{"text": "Baseline HbA1c was available for 1519 patients in the Full Analysis Set ( FAS ) , 764 treated with Linagliptin and 755 patients treated with Glimepiride .", "label": "", "metadata": {}, "score": "23.737297"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .HbA1c Change From Baseline at Week 52 [ units : Percent ] Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "26.491022"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .HbA1c Change From Baseline at Week 104 [ units : Percent ] Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "26.774784"}
{"text": "The placebo - corrected median change from baseline in UACR at week 24 was -8.8 mg / g .Mean ( SD ) SBP decreased by -2.9 ( 0.9 ) mm Hg and -2.4 ( 1.2 ) mm Hg in the linagliptin and placebo groups , respectively , at LVOT ( Table 2 ) .", "label": "", "metadata": {}, "score": "27.849281"}
{"text": "Among patients with microalbuminuria and hypertension , those treated with linagliptin achieved a significantly greater reduction in HbA1c from baseline compared with placebo ( Figure 3 ) .", "label": "", "metadata": {}, "score": "28.750483"}
{"text": "with a reduction in Hba1c of 1.1 % at 24 weeks .There was a greater weight gain with the metformin - glibenclamide group compared with the metformin - rosiglitazone group ( +3.0 kg versus +1.4 kg ) .", "label": "", "metadata": {}, "score": "30.9076"}
{"text": "The Figure 2 exhibits the HbA1c change over time [ 21 ] .Haak et al . reported the findings of early combination of linagliptin and metformin in treatment - na\u00efve diabetic patients , in a 24-week double - blind study [ 22 ] .", "label": "", "metadata": {}, "score": "31.44169"}
{"text": "As observed with other gliptins , the combination with linagliptin to patients inadequately controlled on metformin + sulfonylurea showed a higher occurrence of hypoglycemia than the placebo group ( 22.7 % versus 14.8 % ) [ 27 ] .", "label": "", "metadata": {}, "score": "31.525345"}
{"text": "Regarding baseline HbA1c levels , Westman 's patients ( mean HbA1c level : 8.3 % ) were close to our patients in Group 2 while Gannon 's patients ( mean HA1c level : 10.0 % ) were close to our patients in Group 3 .", "label": "", "metadata": {}, "score": "32.133537"}
{"text": "Last observation carried forward ( LOCF ) was used as imputation rule .Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .", "label": "", "metadata": {}, "score": "32.280807"}
{"text": "In the 52-week follow - up period in that previous study , an HbA1c reduction of -0.44 % was reported in the vildagliptin group and a -0.53 % reduction in the glimepiride group .", "label": "", "metadata": {}, "score": "33.16884"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Percentage of Patients With HbA1c Lowering by 0.5 % at Week 104 [ units : Percentage of patients ] .", "label": "", "metadata": {}, "score": "33.223625"}
{"text": "At baseline , patient demographics and clinical characteristic were similar in the linagliptin and placebo groups ( Table 1 ) .In the overall evaluated population patients had a mean age of 59.5 years , with mean BMI of 29.9 kg / m 2 .", "label": "", "metadata": {}, "score": "33.23843"}
{"text": "In a 12-week analysis , 333 T2DM patients inadequately controlled on metformin monotherapy were randomized to receive linagliptin or glimepiride , in a single daily dose [ 25 ] .", "label": "", "metadata": {}, "score": "33.62906"}
{"text": "In a recent post - hoc analysis of pooled Phase III data , linagliptin significantly reduced UACR after 24 weeks compared with placebo [ 29 ] .", "label": "", "metadata": {}, "score": "33.77076"}
{"text": "Linagliptin was also better than placebo in lowering FPG levels in this population .At week 24 , the adjusted mean change from baseline in FPG was -13.4 ( 2.9 ) mg / dl and 7.9 ( 4.4 ) mg / dl in the linagliptin and placebo groups , respectively .", "label": "", "metadata": {}, "score": "34.430016"}
{"text": "( C ) Mean HbA1c changes during 32 weeks in vildagliptin or glimepiride treatment .FPG 2h PPG Vildagliptin Glimepiride 0 -1 -2 -3 -4 -5 Change from baseline in FPG and 2h - PPG ( mmol / L ) Vildagliptin Glimepiride 0 -0.5 -1 -1.5 Change from baseline in HbA1c ( % )", "label": "", "metadata": {}, "score": "35.320766"}
{"text": "Of 3,119 patients , 512 had both microalbuminuria and hypertension ( linagliptin , 366 ; placebo , 146 ) .The incidence of drug - related adverse events was similar for linagliptin and placebo ( 10.4 % and 8.2 % , respectively ) .", "label": "", "metadata": {}, "score": "35.432297"}
{"text": "In healthy male volunteers , linagliptin ( 2.5 - 600 mg ) demonstrated dose - dependent inhibition of DPP-4 over 24 hours with a 5 mg dose inhibiting 86.1 % of the enzyme activity [ 13 ] .", "label": "", "metadata": {}, "score": "35.70131"}
{"text": "Also , no changes in laboratory parameters or vital signs were observed in different studies with the drug .Moreover , the incidence of cutaneous and subcutaneous changes in linagliptin clinical trials was low when compared to placebo ( 0 - 1.3 % versus 0 - 0.9 % ) [ 13 ] .", "label": "", "metadata": {}, "score": "35.71174"}
{"text": "In patients inadequately controlled on sulfonylurea alone , the addition of linagliptin 5 mg ( single daily dose ) proved more effective than the combination with placebo [ 25 ] .", "label": "", "metadata": {}, "score": "35.756462"}
{"text": "532 Jeon HJ , et al .In the subgroup analysis of baseline HbA1c cate- gory , both treatments showed similar HbA1c reduction effi- ciencies in all categories : greater reductions in HbA1c were noted in patients with higher baseline HbA1c concentrations ( Fig . 2 ) .", "label": "", "metadata": {}, "score": "36.24614"}
{"text": "UACR at baseline was 60 ( 30 - 292 ) mg / g for linagliptin and 64 ( 30 - 298 ) mg / g for placebo .", "label": "", "metadata": {}, "score": "36.62178"}
{"text": "Patients ( mean HbA1c . 7 % , as compared with 36 % in the metformin group and 26 % in the glyburide group [ 16 ] .", "label": "", "metadata": {}, "score": "36.886307"}
{"text": "In a randomized , open - label , comparative study , 106 patients with type 2 diabetes were enrolled .The primary endpoint was a reduction in HbA1c from baseline and secondary endpoints included fasting plasma glucose ( FPG ) or 2-hour postprandial glucose ( 2h - PPG ) reduction from baseline , as well as HbA1c responder rate and HbA1c reduction according to baseline HbA1c category .", "label": "", "metadata": {}, "score": "38.277794"}
{"text": "Garber et al . conducted a 52-week double - blind , double - dummy , active - control , parallel - group study wherein 746 patients with early type 2 diabetes ( mean HbA1c 8.2 % ) were randomized to once - daily subcutaneous liraglutide ( 1.2 mg or 1.8 mg ) or oral glimepiride 8 mg [ 45 ] .", "label": "", "metadata": {}, "score": "38.6567"}
{"text": "Along with these efficacy results , this analysis showed that linagliptin was well tolerated .At baseline , patients in the two treatment groups had well - matched clinical characteristics and similar backgrounds of antihypertensive therapies , with approximately 85 % of each group receiving at least one drug in that class and 13 % of each group receiving combination antihypertensive therapy .", "label": "", "metadata": {}, "score": "38.775543"}
{"text": "More patients in the orlistat group achieved a weight loss of .10 % compared to the placebo group ( 26 % versus 15.6 % ) .", "label": "", "metadata": {}, "score": "38.796516"}
{"text": "The results of linagliptin monotherapy were also better than placebo in the secondary endpoints .There was more reduction in fasting plasma glucose ( FPG ) and 2-hour postprandial glucose ( 2hPPG ) in the linagliptin group .", "label": "", "metadata": {}, "score": "38.8497"}
{"text": "In the study evaluating linagliptin added to metformin and a sulfonylurea , all patients directly entered the 2-week run - in period [ 8 ] .", "label": "", "metadata": {}, "score": "38.98298"}
{"text": "Change over time in HbA1c , following treatment with linagliptin 5 mg or placebo for 24 weeks ( reproduced from Taskinem et al . )[ [ 21 ] ] .", "label": "", "metadata": {}, "score": "39.35399"}
{"text": "Subjects who at end of treatment ( Visit 14 , 4 weeks post Ramadan ) achieve ( y / n ) : HbA1c below 7.0 % ( 53 mmol / mol ) ( ADA target ) .", "label": "", "metadata": {}, "score": "39.38562"}
{"text": "Conclusion .In T2DM patients with the two common vascular risk factors of hypertension and microalbuminuria , linagliptin achieved significant improvements in glycemic control .In this vulnerable patient population at high risk for micro- and macrovascular complications , linagliptin was well tolerated .", "label": "", "metadata": {}, "score": "39.561783"}
{"text": "However , patients on the intensive treatment group had greater weight gain ( mean 2.9 kg ; . 8.7 % ) were randomized to glyburide / metformin therapy ( 1.25/250 mg ) , glyburide ( 2.5 mg ) , or metformin ( 500 mg ) monotherapy with titration to maximum doses for 16 weeks [ 12 ] .", "label": "", "metadata": {}, "score": "39.64752"}
{"text": "The treated set consisted of all patients treated with at least one dose of study drug .Patients randomized to receive Linagliptin 5 mg and metformin .", "label": "", "metadata": {}, "score": "39.824825"}
{"text": "The treated set consisted of all patients treated with at least one dose of study drug .Patients randomized to receive Linagliptin 5 mg and metformin .", "label": "", "metadata": {}, "score": "39.824825"}
{"text": "Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Incidence of Hypoglycaemic Events up to 104 Weeks [ units : Patients ] .", "label": "", "metadata": {}, "score": "40.507362"}
{"text": "1,082 ) with a mean followup of 2.8 years .There was a 58 % reduction in incidence of diabetes in the lifestyle - intervention group and 31 % reduction in the metformin group .", "label": "", "metadata": {}, "score": "40.677555"}
{"text": "Minor changes were observed in lipid parameters in the linagliptin group as compared to the placebo group ( Table 2 ) .Total cholesterol , low - density lipoprotein and high - density lipoprotein showed small but non - significant differences between the groups .", "label": "", "metadata": {}, "score": "40.866398"}
{"text": "The efficacy of linagliptin as monotherapy , compared to placebo , was assessed in two studies of 12 and 24 weeks [ 17 , 18 ] .", "label": "", "metadata": {}, "score": "40.882576"}
{"text": "At the same time , we should not hesitate to impose stricter carbohydrate restriction on patients when necessary .In conclusion , the 3-graded stratification of carbohydrate restriction depending on patients ' baseline HbA1c levels achieved HbA1c levels of around 7.0 % after 6 months despite great differences in baseline HbA1c levels and carbohydrate intake .", "label": "", "metadata": {}, "score": "41.14811"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .", "label": "", "metadata": {}, "score": "41.169235"}
{"text": "At week 24 , dapagliflozin significantly reduced mean HbA1c levels ( -0.5 % [ -4.9 mmol / mol ] ) versus placebo ( 0.0 % [ +0.4 mmol / mol ] ) .", "label": "", "metadata": {}, "score": "41.37954"}
{"text": "Baseline fasting plasma glucose ( FPG ) was available for 1475 patients in the FAS , 740 treated with Linagliptin and 735 patients treated with Glimepiride .", "label": "", "metadata": {}, "score": "41.44279"}
{"text": "More patients on linagliptin also achieved the target HbA1c .The importance of this study in practice is the possibility to improve glycemic control in patients already receiving two oral antidiabetic agents and who are outside the proposed targets [ 27 ] .", "label": "", "metadata": {}, "score": "41.560036"}
{"text": "The present analysis did not evaluate the efficacy or safety of linagliptin by subgroups of renal function , but baseline eGFR data were included to provide a full description of the clinical characteristics of the population with both microalbuminuria and hypertension .", "label": "", "metadata": {}, "score": "41.737328"}
{"text": "Patients in the S100/M2000 group had a reduction in Hba1c of 2.07 % , S100/M1000 group with a reduction of 1.57 % , M2000 group with a reduction of 1.30 % , M1000 group with a reduction of 0.99 % , and S100 group with reduction of 0.83 % .", "label": "", "metadata": {}, "score": "41.868256"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .", "label": "", "metadata": {}, "score": "41.93421"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .", "label": "", "metadata": {}, "score": "41.93421"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .", "label": "", "metadata": {}, "score": "41.93421"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .", "label": "", "metadata": {}, "score": "41.93421"}
{"text": "PubMed Central View Article PubMed .Hocher B , Sharkovska Y , Mark M , Klein T , Pfab T : The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia / reperfusion in rats .", "label": "", "metadata": {}, "score": "41.984344"}
{"text": "Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Incidence of Hypoglycaemic Events up to 52 Weeks [ units : Patients ] .", "label": "", "metadata": {}, "score": "42.2305"}
{"text": "Correlations of changes in HbA1c levels with those in BMI and serum lipid profiles during 6 months in all patients .We found no correlation between \u0394HbA1c and \u0394BMI ( A ) , \u0394serum LDL - cholesterol ( B ) or \u0394serum triglyceride ( C ) , while there was a negative and weak correlation between \u0394HbA1c and \u0394serum HDL - cholesterol ( D ) .", "label": "", "metadata": {}, "score": "42.28888"}
{"text": "Linagliptin , due to its predominantly non - renal route of elimination , requires no dose adjustment .In this post hoc analysis of 512 patients with T2DM at high renal and vascular risk ( defined as prevalent hypertension and microalbuminuria with T2DM ) , linagliptin showed significant and clinically relevant reductions in HbA1c and FPG in comparison with placebo .", "label": "", "metadata": {}, "score": "42.36081"}
{"text": "Aschner et al .evaluated the efficacy of sitagliptin as monotherapy in type 2 diabetes patients in a double - blind , placebo - controlled study [ 50 ] .", "label": "", "metadata": {}, "score": "42.701992"}
{"text": "Over a period of 5 years , treatment with rosiglitazone resulted in an average weight gain of 4.8 kg versus 1.6 kg in the glyburide group whereas patients on metformin had a decrease in weight ( . 2.9 kg ) .", "label": "", "metadata": {}, "score": "42.844673"}
{"text": "Less than 1 % of subjects experienced hypoglycemia when linagliptin was administered as monotherapy or in addition to metformin or pioglitazone .However , when linagliptin was administered with a sulfonylurea , the number of patients experiencing hypoglycemia was greater than with placebo ( linagliptin , 19.8 % and placebo , 5.9 % ) .", "label": "", "metadata": {}, "score": "42.97533"}
{"text": "In the present study , the efficacy and safety of vildagliptin- metformin treatment compared to those of glimepiride - met- formin treatment were evaluated over 32 weeks in type 2 dia- betic patients .", "label": "", "metadata": {}, "score": "43.22677"}
{"text": "View Article PubMed .Johansen OE , Neubacher D , von Eynatten M , Patel S , Woerle H - J : Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus : a pre - specified , prospective , and adjudicated meta - analysis of a phase 3 programme .", "label": "", "metadata": {}, "score": "43.280403"}
{"text": "In the extended two - year obser- vation period in the previous study , the vildagliptin - metfor- min combination treatment group still evidenced similar glu- cose control and better safety profiles [ 22].", "label": "", "metadata": {}, "score": "43.492603"}
{"text": "Nauck MA , Meininger G , Sheng D , Terranella L , Stein PP ; Si- tagliptin Study 024 Group .Efficacy and safety of the dipeptidyl peptidase-4 inhibitor , sitagliptin , compared with the sulfonyl- urea , glipizide , in patients with type 2 diabetes inadequately controlled on metformin alone : a randomized , double - blind , non - inferiority trial .", "label": "", "metadata": {}, "score": "43.50876"}
{"text": "In the treated set , the overall incidences of any AE and serious AEs were comparable between both treatment groups ( linagliptin , 62.6 % and placebo , 62.3 % ; linagliptin , 4.1 % and placebo , 6.2 % ) .", "label": "", "metadata": {}, "score": "43.66707"}
{"text": "In order to specifically evaluate the albumin - lowering potential of linagliptin a randomized , controlled trial has recently been initiated ( clinicaltrials.gov : NCT01792518 , MARLINA ) .", "label": "", "metadata": {}, "score": "43.710968"}
{"text": "Graefe - Mody et al .evaluated in a randomized , open - label , crossover , single - center study , the potential pharmacokinetic and pharmacodynamic interaction between metformin and linagliptin .", "label": "", "metadata": {}, "score": "43.763653"}
{"text": "This study suggested that the combination of metformin and linagliptin can be done safely in patients with T2DM , without requiring dose adjustment [ 20 ] .", "label": "", "metadata": {}, "score": "43.8021"}
{"text": "Regarding safety , the vildagliptin - metformin treatment had a favorable hypoglycemic profile : a 10-fold lower incidence of hypoglycemia , with no severe hypoglycemia observed .", "label": "", "metadata": {}, "score": "43.843853"}
{"text": "The sibutramine - treated group had greater weight loss compared to placebo ( 8.1 kg versus 5.1 kg ) .More patients on the sibutramine group lost more than 5 % ( 62 % versus 41 % ) and 10 % ( 40 % versus 19 % ) of their baseline weight compared to placebo .", "label": "", "metadata": {}, "score": "44.00743"}
{"text": "Mean HbA1c reduction according to the baseline HbA1c category .Page 5 .The propor- tions of patients who achieved an HbA1c of less than 7.0 % and HbA1c reduction according to the baseline HbA1c category were similar between treatments .", "label": "", "metadata": {}, "score": "44.069794"}
{"text": "We then analyzed the changes in glucose parameters and clinical characteristics .Ultimately , 327 subjects were analyzed in this study .Vildagliptin significantly improved hemoglobin A1c ( HbA1c ) levels over 6 months .", "label": "", "metadata": {}, "score": "44.087883"}
{"text": "A direct comparison will be required to determine whether more detailed stratification of carbohydrate restriction by levels of baseline HbA1c can allow patients with lower HbA1c levels to avoid unnecessarily strict restriction of carbohydrate intake and still achieve sufficient glycemic control .", "label": "", "metadata": {}, "score": "44.11482"}
{"text": "View Article PubMed .Owens DR , Swallon R , Dugi KA , Woerle HJ : Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24-week randomized study .", "label": "", "metadata": {}, "score": "44.212208"}
{"text": "Sitagliptin at doses of 100 or 200 mg had a significant reduction in HbA1c of 0.69 and 0.94 % , respectively , with no significant change in body weight .", "label": "", "metadata": {}, "score": "44.27973"}
{"text": "In clinical trial populations that included patients with mild and moderate renal impairment , linagliptin has been shown to be an efficacious and well - tolerated treatment without dose adjustment [ 7 , 9 , 15 ] .", "label": "", "metadata": {}, "score": "44.350414"}
{"text": "An important conclusion is that , as other DPP-4 inhibitors have also demonstrated , linagliptin shows no increase in CV risk [ 35 ] .At present , various studies with DPP-4 inhibitors are currently ongoing to evaluate the safety and effects on cardiovascular endpoints ( Table 3 ) [ 8 ] .", "label": "", "metadata": {}, "score": "44.54039"}
{"text": "Efficacy measurements after start of rescue were replaced by missing values .Results .Patient demographics .Across the six studies , 3,119 patients were treated with either linagliptin 5 mg once daily ( 2,222 ) or placebo ( 897 ) .", "label": "", "metadata": {}, "score": "44.85354"}
{"text": "The addition of metformin resulted in the reduction of HbA1c by 1.4 % versus 0.4 % in the placebo group at 29 weeks .The metformin group experienced weight loss of 0.6 kg whereas the placebo group had a weight reduction of 1.1 kg .", "label": "", "metadata": {}, "score": "44.91639"}
{"text": "An HbA1c of 48 mmol / mol ( 6.5 % ) is recommended as the cut point for diagnosing diabetes .However , a value of less than 48 mmol / mol ( 6.5 % ) does not exclude diabetes diagnosed using glucose tests .", "label": "", "metadata": {}, "score": "44.922073"}
{"text": "Data are shown as mean \u00b1 SD .The participants were divided into three groups according to baseline hemoglobin A1c .Correlations of HbA1c levels with macronutrients at baseline .", "label": "", "metadata": {}, "score": "44.94204"}
{"text": "Under such circumstances , \u0394carbohydrate ( g / day ) was correlated with \u0394HbA1c independently of \u0394total energy intake [ 20 ] .Based on the results for the above nutritional changes , the 3-graded moderate LCD achieved good glycemic control - HbA1c levels of around 7.0 % after 6 months in all groups despite the variation in baseline HbA1c levels - without reinforcement by anti - diabetic drugs .", "label": "", "metadata": {}, "score": "45.02096"}
{"text": "This population includes the FAS further restricted to patients with a baseline FPG and one on - treatment FPG measurement .Last observation carried forward ( LOCF ) was used as imputation rule .", "label": "", "metadata": {}, "score": "45.057827"}
{"text": "However , the type of basal insulin used may have different effects on weight .Rosenstock et al .compared the efficacy of insulin analogs detemir and glargine when added to oral glucose - lowering agents in insulin - na\u00efve type 2 diabetes subjects with baseline HbA1c of 8.6 % in a 52-week , open - label treat - to - target trial [ 23 ] .", "label": "", "metadata": {}, "score": "45.08364"}
{"text": "Research suggests that GLP-1 may have beneficial effects on dyslipidemia , and recent small studies with DPP-4 inhibitors have shown favorable effects [ 24 , 25 ] or a neutral effect [ 26 ] on postprandial dyslipidemia in patients with T2DM .", "label": "", "metadata": {}, "score": "45.323795"}
{"text": "Gastrointestinal AEs and infections , which are of concern in the DPP-4 class , occurred in similar proportions of patients in the linagliptin and placebo groups .", "label": "", "metadata": {}, "score": "45.325447"}
{"text": "PubMed Central View Article PubMed .Schernthaner G , Barnett AH , Emser A , Patel S , Troost J , Woerle HJ , von Eynatten M : Safety and tolerability of linagliptin : a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "45.411446"}
{"text": "with orlistat .Liraglutide decreased the prevalence of prediabetes ( impaired fasting glucose or impaired glucose tolerance ) by 84 - 96 % with 1.8 to 3 mg per day .", "label": "", "metadata": {}, "score": "45.523926"}
{"text": "There was a dose - dependent reduction in body weight with 1.2 and 1.8 mg liraglutides ( . were randomized to once - daily liraglutide ( 1.2 mg or 1.8 mg ) or placebo in addition to metformin ( 1 g BID ) and rosiglitazone ( 4 mg BID ) [ 46 ] .", "label": "", "metadata": {}, "score": "45.56727"}
{"text": "10.1111/j.1463 - 1326.2010.01326.x .View Article PubMed .Haak T , Meinicke T , Jones R , Weber S , von Eynatten M , Woerle HJ : Initial combination of linagliptin and metformin improves glycemic control in type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "45.568474"}
{"text": "Of the 5239 patients , 3319 received linagliptin , and 1920 received a comparator ( placebo , glimepiride , voglibose ) [ 35 ] .A composite of CV death , stroke , MI , or hospitalization for unstable angina was considered as the primary endpoint .", "label": "", "metadata": {}, "score": "45.574562"}
{"text": "All patients provided written informed consent before participation .Efficacy was assessed by the change from baseline in HbA1c and fasting plasma glucose ( FPG ) at 18 and 24 weeks of treatment .", "label": "", "metadata": {}, "score": "45.61153"}
{"text": "Conclusion : Vildagliptin - metformin treatment provided blood glucose control efficacy comparable to that of glimepiride - met- formin treatment and resulted in better adverse event profiles with lower risks of hypoglycemia and weight gain .", "label": "", "metadata": {}, "score": "45.708168"}
{"text": "( A )Mean fasting plasma glucose ( FPG ) and 2-hour post - prandial glucose ( 2h - PPG ) reduction in vildagliptin or glimepiride treatment .", "label": "", "metadata": {}, "score": "45.795235"}
{"text": "The primary end- point was a reduction in HbA1c from baseline and secondary endpoints included fasting plasma glucose ( FPG ) or 2-hour post- prandial glucose ( 2h - PPG ) reduction from baseline , as well as HbA1c responder rate and HbA1c reduction according to baseline HbA1c category .", "label": "", "metadata": {}, "score": "45.91684"}
{"text": "Twenty - five ( 61 % ) of the 41 patients in Group 2 were taking anti - diabetic drugs at baseline , but the number of patients on anti - diabetic drugs decreased from 25 to 12 during the 6 months , a more remarkable reduction than in the other 2 groups .", "label": "", "metadata": {}, "score": "45.965614"}
{"text": "2012 , [ Epub ahead of print ] .Cardiovasc Res .10.1093/cvr / cvs246 .View Article PubMed .Ring A , Graefe - Mody U , Port A , Revollo I , Iovino M , Dugi KA : The DPP-4 inhibitor linagliptin does not prolong the QT interval with therapeutic and supratherapeutic doses .", "label": "", "metadata": {}, "score": "46.085583"}
{"text": "View Article PubMed .Taskinen MR , Rosenstock J , Tamminen I , Kubiak R , Patel S , Dugi KA , Woerle HJ : Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "46.095245"}
{"text": "Bolli G , Dotta F , Rochotte E , Cohen SE .Efficacy and tolerabili- ty of vildagliptin vs. pioglitazone when added to metformin : a 24-week , randomized , double - blind study .", "label": "", "metadata": {}, "score": "46.15413"}
{"text": "However , taken together with previous reports of up to 2 years in patients with T2DM [ 7 - 9 , 13 - 15 , 34 ] , these results provide further evidence of beneficial glycemic effects and tolerability in this population .", "label": "", "metadata": {}, "score": "46.170135"}
{"text": "A -74 g - carbohydrate restriction in this group produced a -0.4 % reduction in HbA1c after 6 months .If we had adopted the previous 2-graded moderate LCD , Group 1 would have been subjected to a -117 g - carbohydrate restriction .", "label": "", "metadata": {}, "score": "46.236515"}
{"text": "The study protocol was re- viewed and approved by the Institutional Review Board of Chungbuk National University Hospital .Eligible patients were assigned randomly at a 1:1 ratio at baseline ( day 0 ) to receive either 50 mg of vildagliptin twice daily or 2 mg glimepiride twice daily in addition to 500 mg of metformin twice daily for 32 weeks .", "label": "", "metadata": {}, "score": "46.288036"}
{"text": "There was a progressive reduction in weight of 6.1 .10 % of baseline weight .These data are encouraging in that weight control is possible with the use of amylin analogs in patients inadequately controlled on insulin therapy .", "label": "", "metadata": {}, "score": "46.33149"}
{"text": "A meta - analysis of linagliptin phase III studies showed no increased cardiovascular risk with linagliptin [ 10 ] .A pooled analysis of data from eight phase III studies with linagliptin provided additional confirmation that linagliptin is well tolerated in patients with or without renal dysfunction [ 11 ] .", "label": "", "metadata": {}, "score": "46.344887"}
{"text": "This study showed that linagliptin has the same efficacy as sulfonylureas , without risk of weight gain and hypoglycemia [ 25 ] .Safety and tolerability .", "label": "", "metadata": {}, "score": "46.50938"}
{"text": "At 32 weeks , body weight was unchanged in the vildagliptin - metformin treatment group , whereas the patients treated with glimepiride - metformin evi- denced weight increase ( 2.35 kg ) relative to baseline .", "label": "", "metadata": {}, "score": "46.596596"}
{"text": "The reduction in HbA1c from baseline to week 12 ( .Liraglutide is more recently approved by FDA ( January 2010 ) to be used as a once - daily subcutaneous injection for type 2 diabetes .", "label": "", "metadata": {}, "score": "46.767517"}
{"text": "Am J Kidney Dis .View Article .Del Prato S , Barnett AH , Huisman H , Neubacher D , Woerle HJ , Dugi KA : Effect of linagliptin monotherapy on glycaemic control and markers of beta - cell function in patients with inadequately controlled type 2 diabetes : a randomized controlled trial .", "label": "", "metadata": {}, "score": "46.775208"}
{"text": "In plasma , most gliptins exhibit low binding rate to proteins [ 9 ] .Linagliptin , in turn , extensively binds to plasma proteins , and at the therapeutic dose of 5 mg , most of the drug is bound to proteins [ 9 ] .", "label": "", "metadata": {}, "score": "47.081795"}
{"text": "Several studies were also conducted to determine the effect of orlistat in patients with type 2 DM .Jacob et al . conducted a multicenter double - blind , placebo - controlled study in which overweight or obese patients with type 2 diabetes ( mean HbA1c . 0.14 % ) suggesting that improvement of glycemic control associated with orlistat may be independent of weight loss .", "label": "", "metadata": {}, "score": "47.081837"}
{"text": "Overweight or obese , nondiabetic subjects . 0.5 kg ) with no significant change in HbA1c .However , in subjects who lost more than 10 % of their body weight , there was a significant decrease in HbA1c averaging 1.2 % .", "label": "", "metadata": {}, "score": "47.125557"}
{"text": "In a 52-week , randomized , double - blind placebo - controlled study in which type 2 diabetes patients . treated with metformin alone or in combination with sulfonylurea were randomized to orlistat versus placebo [ 56 ] .", "label": "", "metadata": {}, "score": "47.291565"}
{"text": "JAMA .10.1001/jama.281.21.2005 .View Article PubMed .Graefe - Mody EU , Padula S , Ring A , Withopf B , Dugi KA : Evaluation of the potential for steady - state pharmacokinetic and pharmacodynamics interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects .", "label": "", "metadata": {}, "score": "47.58178"}
{"text": "2012 , Oct , 55 ( Suppl 1 ) : S20 .Chan JC , Scott R , Arjona Ferreira JC , Sheng D , Gonzalez E , Davies MJ , Stein PP , Kaufman KD , Amatruda JM , Williams - Herman D : Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency .", "label": "", "metadata": {}, "score": "47.665604"}
{"text": "The results were relatively close to each other in spite of the great difference in HbA1c levels and carbohydrate intakes at baseline , which ranged from 6.5 to 14.1 % and 140 to 579 g / day at baseline , respectively .", "label": "", "metadata": {}, "score": "47.711647"}
{"text": "Hypoglycemia .DPP-4 inhibitors have a low risk of hypoglycemia due to their effect as glucose - dependent insulin secretagogue .The incidence of hypoglycaemia was 8.2 % in patients receiving linagliptin and 5.1 % in those receiving placebo .", "label": "", "metadata": {}, "score": "48.19381"}
{"text": "They will allow us to give clear and accurate goals for carbohydrate delta - reduction from baseline to individual patients .If a patient could not achieve an individual optimal target HbA1c level after 3 - 6 months , we would modify the quantity of daily carbohydrate intake based on the current findings .", "label": "", "metadata": {}, "score": "48.222305"}
{"text": "PubMed .Clin Ther .2012 , 1909 - 1919 : e1915 .Gomis R , Espadero RM , Jones R , Woerle HJ , Dugi KA : Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "48.227364"}
{"text": "Statistical analysis .Efficacy endpoints were evaluated with an analysis of covariance ( ANCOVA ) .The general model contained the following factors : treatment , washout of prior OAD and study , as well as the linear covariate continuous baseline HbA1c .", "label": "", "metadata": {}, "score": "48.507034"}
{"text": "Kawamori et al . also compared linagliptin monotherapy with voglibose , an \u03b1 - glucosidase inhibitor , in a 26-week study [ 17 ] .", "label": "", "metadata": {}, "score": "48.57416"}
{"text": "Patients randomized to receive Linagliptin 5 mg and metformin .Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Fasting Plasma Glucose ( FPG )", "label": "", "metadata": {}, "score": "48.576927"}
{"text": "10.1111/j.1463 - 1326.2011.01382.x .View Article PubMed .Diabetes Obes Metab .10.1111/j.1463 - 1326.2011.01458.x .View Article PubMed .McGill JB , Sloan L , Newman J , Patel S , Sauce C , von Eynatten M , Woerle HJ : Long - term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment : a 1-year , randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "48.847145"}
{"text": "In an analysis of 3 Phase III , randomized , placebo - controlled studies , the effect of renal function on the efficacy and safety of linagliptin was evaluated .", "label": "", "metadata": {}, "score": "48.920013"}
{"text": "in addition to their antidiabetes agents .Following the 34.5-month study period , the pioglitazone group achieved a reduction in HbA1c of 0.8 % compared with 0.3 % in the placebo group despite the addition of more antidiabetes agents in the placebo group [ 15 ] .", "label": "", "metadata": {}, "score": "48.998615"}
{"text": "The risk of adverse events with linagliptin monotherapy is similar to placebo .Its effect on body weight is considered neutral and the hypoglycemia occurrence is very low .", "label": "", "metadata": {}, "score": "49.07566"}
{"text": "Methods .Participants received linagliptin 5 mg daily ( alone or in combination with other oral antidiabetic drugs ) or placebo for 18 to 24 weeks .", "label": "", "metadata": {}, "score": "49.099365"}
{"text": "1224 - 1230 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus . D. Russell - Jones , A. Vaag , O. Schmitz et al . , \" Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus ( LEAD-5 met+SU ) : a randomised controlled trial , \" Diabetologia , vol .", "label": "", "metadata": {}, "score": "49.21933"}
{"text": "The current study demonstrates that baseline HbA1c levels were correlated with carbohydrate intake ( g / day ) but not with % carbohydrate .Also , \u0394carbohydrate ( g / day ) was very strongly ( inversely ) correlated with baseline carbohydrate intake ( g / day ) , but weakly with \u0394%carbohydrate , and \u0394HbA1c was strongly correlated with \u0394carbohydrate ( g / day ) , but weakly with \u0394%carbohydrate .", "label": "", "metadata": {}, "score": "49.257896"}
{"text": "Additionally , HbA1c remained stable until the endpoint at week 32 ( Fig .1C ) .The proportions of patients who achieved an HbA1c less Table 1 .", "label": "", "metadata": {}, "score": "49.259727"}
{"text": "However , as has been shown in a number of prospective trials including the United Kingdom Prospective Diabetes Study ( UKPDS ) , intensive glucose control is associated with a median weight gain of 3 - 3.5 kg .", "label": "", "metadata": {}, "score": "49.357677"}
{"text": "20 , no .4 , pp .597 - 606 , 1997 .View at Google Scholar \u00b7 View at Scopus . A. J. Garber , D. S. Donovan Jr. , P. Dandona , S. Bruce , and J.-S. Park , \" Efficacy of glyburide / metformin tablets compared with initial monotherapy in type 2 diabetes , \" Journal of Clinical Endocrinology and Metabolism , vol . 88 , no . 8 , pp .", "label": "", "metadata": {}, "score": "49.489544"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .Change in Baseline Lipid Parameter HDL at Week 104 [ units : mg / dl ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "49.50602"}
{"text": "In conclusion , in patients with T2DM complicated by hypertension and microalbuminuria , linagliptin 5 mg once daily is well tolerated and improves glycemic control .", "label": "", "metadata": {}, "score": "49.57046"}
{"text": "123 - 131 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Fineman , C. Weyer , D. G. Maggs , S. Strobel , and O. G. Kolterman , \" The human amylin analog , pramlintide , reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus , \" Hormone and Metabolic Research , vol .", "label": "", "metadata": {}, "score": "49.572426"}
{"text": "This population includes the FAS further restricted to patients with a baseline body weight and one on - treatment body weight measurement .Last observation carried forward ( LOCF ) was used as imputation rule .", "label": "", "metadata": {}, "score": "49.573326"}
{"text": "This population includes the FAS further restricted to patients with a baseline body weight and one on - treatment body weight measurement .Last observation carried forward ( LOCF ) was used as imputation rule .", "label": "", "metadata": {}, "score": "49.573326"}
{"text": "10.1111/j.1463 - 1326.2010.01350.x .View Article PubMed .Owens DR , Swallow R , Dugi KA , Woerle HJ : Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea : a 24-week randomized study .", "label": "", "metadata": {}, "score": "49.74648"}
{"text": "View Article PubMed .Huttner S , Graefe - Mody EU , Withopf B , Ring A , Dugi KA : Safety , tolerability , pharmacokinetics and pharmacodynamics of single oral doses of BI1356 , an inhibitor of dipeptidyl peptidase 4 , in healthy male volunteers .", "label": "", "metadata": {}, "score": "49.75582"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .Change in Baseline Lipid Parameter Triglyceride at Week 104 [ units : mg / dL ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "49.781784"}
{"text": "10.1111/j.1463 - 1326.2012.01590.x .View Article PubMed .Diabet Med .10.1111/j.1464 - 5491.2010.03131.x .View Article PubMed .Gomis R , Espadero RM , Jones R , Woerle HJ , Dugi KA : Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "49.81566"}
{"text": "Results . \u0394HbA1cand \u0394carbohydrate were -0.4 \u00b1 0.4 % and -74 \u00b1 69 g / day for Group 1 , -0.6 \u00b1 0.9 % and -117 \u00b1 78 g / day for Group 2 and -3.1 \u00b1 1.4 % and -156 \u00b1 74 g / day for Group 3 .", "label": "", "metadata": {}, "score": "49.82491"}
{"text": "10.1620/tjem.223.133 .View Article PubMed .Diabetes Care . 10.2337/dc11 - 1107 .PubMed Central View Article PubMed .Groop P - H , Cooper M , Perkovic V , Emser A , Seck T , von Eynatten M , Woerle H - J : Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy .", "label": "", "metadata": {}, "score": "49.886578"}
{"text": "The use of TZDs and metformin as an insulin - sensitizing strategy as compared to an insulin - providing strategy with SUs and insulin employed in diabetic patients with coronary artery disease enrolled in the BARI 2D trial had a greater likelihood of achieving glycemic control with HbA1c .", "label": "", "metadata": {}, "score": "49.97928"}
{"text": "Methods .This post hoc analysis pooled patient data from six randomized , double - blind , placebo - controlled , phase III trials from the linagliptin clinical trial program .", "label": "", "metadata": {}, "score": "50.011593"}
{"text": "Recent studies also demonstrated that intensive control may be associated with increased cardiovascular ( CV ) risk ; therefore , another potential benefit of gliptins would be a low risk of hypoglycemia [ 35 ] .", "label": "", "metadata": {}, "score": "50.016182"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Body Weight Change From Baseline at Week 52 [ units : kg ] Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "50.08367"}
{"text": "6 , pp . 1033 - 1041 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. J. Aronne , A. E. Halseth , C. M. Burns , S. Miller , and L. Z. Shen , \" Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial , \" Obesity , vol .", "label": "", "metadata": {}, "score": "50.152245"}
{"text": "View Article PubMed .Diabetes Obes Metab .10.1111/j.1463 - 1326.2011.01545.x .View Article PubMed .Del Prato S , Barnett AH , Huisman H , Neubacher D , Woerle HJ , Dugi KA : Effect of linagliptin monotherapy on glycemic control and markers of beta cell function in patients with inadequately controlle type 2 diabetes : a randomized controlled trial .", "label": "", "metadata": {}, "score": "50.210815"}
{"text": "g BID produced a significant reduction in HbA1c of 0.68 % at week 26 which was sustained at week 52 .This effect was accompanied by a mean weight loss of 1.4 kg compared with a weight gain of 0.7 kg in the placebo group . 1.1 kg , respectively , at 4 months .", "label": "", "metadata": {}, "score": "50.21573"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .2 hr Postprandial Glucose ( PPG ) Change From Baseline at Week 104 [ units : mg / dL ] Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "50.2391"}
{"text": "Page 3 .One patient in the glimepiride - metformin group and three patients in the vildagliptin - metformin group were eliminated from the study in the first four weeks due to recurrent hypoglycemia or intolerable gastrointestinal ( GI ) trouble , respectively .", "label": "", "metadata": {}, "score": "50.304764"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Body Weight Change From Baseline at Week 104 [ units : kg ] Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "50.4188"}
{"text": "333 , no . 9 , pp .541 - 549 , 1995 .View at Google Scholar . A. Garber , E. Klein , S. Bruce , S. Sankoh , and P. Mohideen , \" Metformin - glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy , \" Diabetes , Obesity and Metabolism , vol . 8 , no . 2 , pp .", "label": "", "metadata": {}, "score": "50.468826"}
{"text": "A last observation carried forward ( LOCF ) approach was used to handle missing values for the calculation of the placebo - corrected mean change in HbA1c at week 18 and week 24 and the placebo - corrected mean change in FPG at week 24 .", "label": "", "metadata": {}, "score": "50.538036"}
{"text": "8 % is 64 mmol / mol and 9 % is 75 mmol / mol .These methods work well for HbA1c from 4 % up to 13 % which is the case for the majority of patients with diabetes presenting to our clinics .", "label": "", "metadata": {}, "score": "50.62813"}
{"text": "Furthermore , linagliptin has anti - oxidant properties , probably due to its xanthine - based molecular structure [ 37 ] .Even when administered in supratherapeutic doses , linagliptin does not prolong the QT interval [ 38 ] .", "label": "", "metadata": {}, "score": "50.78469"}
{"text": "The findings of this study are limited by the post hoc pooled nature of the analysis .Patients who participated in any of six randomized , placebo - controlled , phase III trials , had different background antidiabetic therapies .", "label": "", "metadata": {}, "score": "50.853065"}
{"text": "Chemical structure .The DPP-4 inhibitors can be divided , according to their chemical structure , into those that mimic the DPP-4 molecule ( vildagliptin and saxagliptin ) and those that do not ( sitagliptin , alogliptin , and linagliptin ) .", "label": "", "metadata": {}, "score": "50.876427"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .Change in Baseline Lipid Parameter Low Density Lipoprotein ( LDL ) at Week 104 [ units : mg / dL ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "50.94812"}
{"text": "No deaths occurred in either treatment group of the population of patients with microalbuminuria and hypertension .A list of AEs by system - organ class is presented in Table 3 . 2 of these events were considered drug - related ( 2 cases of hypertension ; 1 with linagliptin and 1 with placebo ) .", "label": "", "metadata": {}, "score": "51.022633"}
{"text": "10.1111/j.1463 - 1326.2011.01458.x .View Article PubMed .McGill JB , Sloan L , Newman J , Patel S , Sauce C , Von Eynatten M , Woerle HJ : Long - term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment : a 1-year , randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "51.17309"}
{"text": "This trial will include patients with vascular - related end - organ damage ( such as moderate renal dysfunction or microalbuminuria ) as well as patients with prevalent cardiovascular risk factors , such as hypercholesterolemia or hypertension , and will allow for long - term safety assessments .", "label": "", "metadata": {}, "score": "51.19051"}
{"text": "In a recent study , vildagliptin decreased FPG levels [ 24 ] ; its effect was inferior to that of thiazolidinediones , metformin , and sulfonylureas , and this observation may be attributed to the specific activities of vildagliptin on postprandial sugars , such as acarbose and glinides .", "label": "", "metadata": {}, "score": "51.22856"}
{"text": "Fonseca V , Baron M , Shao Q , Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "51.276253"}
{"text": "In another trial , the Action in Diabetes and Vascular Dis- ease : Preterax and Diamicron Modified Release Controlled Evaluation ( ADVANCE ) , severe hypoglycemia was strongly associated with increased risks of adverse clinical outcomes .", "label": "", "metadata": {}, "score": "51.31678"}
{"text": "View Article .Daly ME , Paisey R , Millward BA , Eccles C , Williams K , Hammersley S , MacLeod KM , Gale TJ : Short - term effects of severe dietary carbohydrate - restriction advice in type 2 diabetes - a randomized controlled trial .", "label": "", "metadata": {}, "score": "51.458977"}
{"text": "Baseline characteristics of patients according to their baseline HbA1c levels .The baseline characteristics of the 122 patients including clinical and biological parameters are shown in Table 1 .", "label": "", "metadata": {}, "score": "51.48717"}
{"text": "Baseline HbA1c levels were positively correlated with baseline carbohydrate intake ( g / day ) ( A ) .\u0394carbohydrate intake ( g / day ) was inversely and very strongly correlated with baseline carbohydrate intake ( g / day ) with consumption of the moderate LCDs ( B ) .", "label": "", "metadata": {}, "score": "51.49843"}
{"text": "Due to multiple testing of the primary endpoints at weeks 52 and 104 a Bonferroni correction was applied and 97.5 % confidence intervals produced .This 1-sided p - value for non - inferiority should be compared to the 1-sided threshold of 0.0125 .", "label": "", "metadata": {}, "score": "51.656906"}
{"text": "10.1001/jama.2009.460 .View Article .Gannon MC , Hoover H , Nuttall FQ : Further decrease in glycated hemoglobin following ingestion of a LoBAG30 diet for 10 weeks compared to 5 weeks in people with untreated type 2 diabetes .", "label": "", "metadata": {}, "score": "51.788506"}
{"text": "Correlations of \u0394HbA1c with \u0394carbohydrate .For all patients , \u0394HbA1c was positively correlated with \u0394carbohydrate ( g / day ) ( A ) and \u0394%carbohydrate ( B ) .", "label": "", "metadata": {}, "score": "51.80827"}
{"text": "Monotherapy with metformin reduced the HbA1c up to 1.5 % [ 25 ] .DeFronzo et al . conducted a two - parallel - group , double - blind study to determine the efficacy of metformin in moderately obese patients with diabetes uncontrolled with diet or diet plus glyburide .", "label": "", "metadata": {}, "score": "51.81759"}
{"text": "10.1111/j.1464 - 5491.2011.03387.x .View Article PubMed .Taskinen MR , Rosenstock J , Tamminen I , Kubiak R , Patel S , Dugi KA , Woerle HJ : Safety and efficacy of linagliptin as add - on therapy to metformin in patients with type 2 diabetes : a randomized , double - blind , placebo - controlled study .", "label": "", "metadata": {}, "score": "51.9736"}
{"text": "Diabetes Obes Metab 2009;11:157 - 66 .Diabetes Obes Metab 2010;12:780 - 9 .Dejager S , Razac S , Foley JE , Schweizer A. Vildagliptin in drug - na\u00efve patients with type 2 diabetes : a 24-week , double- blind , randomized , placebo - controlled , multiple - dose study .", "label": "", "metadata": {}, "score": "52.043858"}
{"text": "In a 26-week , multinational , parallel - group trial , liraglutide was compared to glargine in addition to metformin and sulfonylurea [ 47 ] .", "label": "", "metadata": {}, "score": "52.057327"}
{"text": "Study , a 4-year double - blind , prospective study , was conducted to determine the long - term effect of orlistat in reducing progression to type 2 diabetes [ 54 ] .", "label": "", "metadata": {}, "score": "52.170124"}
{"text": "Number who started treatment .One patient in the Linagliptin group was randomized but not treated .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "52.185097"}
{"text": "Table 2 .Data are shown as mean \u00b1 SD .The participants were divided into 3 groups according to baseline hemoglobin A1c levels .The parameter change for each biomarker ( \u0394 ) was defined as the level after 6 months minus the level at baseline .", "label": "", "metadata": {}, "score": "52.213158"}
{"text": "However , combination with SUs or TZDs may result in weight gain whereas the combination with GLP-1 analogs may enhance weight loss .Amylin Analogs .", "label": "", "metadata": {}, "score": "52.31839"}
{"text": "In this retrospective study , we retrieved data for subjects who were on twice - daily 50 mg vildagliptin for at least 6 months , and classified the subjects into five treatment groups .", "label": "", "metadata": {}, "score": "52.34065"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Measured Values .Change in Baseline Lipid Parameter Cholesterol at Week 104 [ units : mg / dL ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "52.436493"}
{"text": "Among patients with microalbuminuria , the study found an annual cardiovascular mortality rate of 2.0 % compared with 3.5 % in those with macroalbuminuria .International guidelines for the treatment of T2DM recommend reducing the risk or slowing the progression of kidney disease through optimization of glycemic control [ 19 ] .", "label": "", "metadata": {}, "score": "52.47368"}
{"text": "View Article PubMed .Graefe - Mody U , Friedrich C , Port A : Effect or renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin .", "label": "", "metadata": {}, "score": "52.488297"}
{"text": "10.1111/j.1464 - 5491.2011.03387.x .View Article PubMed .Schernthaner G , Barnett AH , Emser A , Patel S , Troost J , Woerle HJ , von Eynatten M : Safety and tolerability of linagliptin : a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "52.573906"}
{"text": "A similar reduction in 2h - PPG ( vildagliptin group 3.53\u00b14.11 mmol / L vs. the glimepiride group 3.72\u00b14.17 mmol / L ) was demonstrated , and the decrements in FPG ( vildagliptin group 1.54\u00b12.41 mmol / L vs. glimepiride group 2.16\u00b12.51 mmol / L ) were not different between groups .", "label": "", "metadata": {}, "score": "52.663292"}
{"text": "A similar reduction in 2h - PPG ( vildagliptin group 3.53\u00b14.11 mmol / L vs. the glimepiride group 3.72\u00b14.17 mmol / L ) was demonstrated , and the decrements in FPG ( vildagliptin group 1.54\u00b12.41 mmol / L vs. glimepiride group 2.16\u00b12.51 mmol / L ) were not different between groups .", "label": "", "metadata": {}, "score": "52.663292"}
{"text": "An average body weight gain of 2.53\u00b11.21 kg in the glimepiride group was observed in contrast with the 0.23\u00b10.69 kg weight gain noted in the vildagliptin group .", "label": "", "metadata": {}, "score": "52.797462"}
{"text": "An average body weight gain of 2.53\u00b11.21 kg in the glimepiride group was observed in contrast with the 0.23\u00b10.69 kg weight gain noted in the vildagliptin group .", "label": "", "metadata": {}, "score": "52.797462"}
{"text": "Orlistat weight loss is associated with improvements in cardiovascular co - morbidities , and hence cardiovascular risk ... .Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults : a randomized , placebo - controlled trial .", "label": "", "metadata": {}, "score": "52.923874"}
{"text": "Vildagliptin - metformin treatment provided blood glucose control efficacy comparable to that of glimepiride - metformin treatment and resulted in better adverse event profiles with lower risks of hypoglycemia and weight gain .", "label": "", "metadata": {}, "score": "53.00449"}
{"text": "Liraglutide 1.8 mg resulted in a mean weight loss of 1.8 kg from baseline compared with 0.42 kg in the placebo group .Patients on insulin glargine gained 1.6 kg .", "label": "", "metadata": {}, "score": "53.013123"}
{"text": "Genomes and Genes .Species .J Wilding .Summary .Publications .Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "53.079273"}
{"text": "10.2337/db09 - 9028 .PubMed Central View Article PubMed .Kalra S , Unnikrishnan AG , Agrawal N , Singh AK : Linagliptin and newer DPP-4 inhibitors : newer uses and newer indications .", "label": "", "metadata": {}, "score": "53.166206"}
{"text": "evaluated the efficacy of sibutramine in combination with oral hypoglycemic agents in obese patients with poorly controlled type 2 diabetes ( mean HbA1c . 0.91 kg ) .", "label": "", "metadata": {}, "score": "53.389"}
{"text": "Also , no dose adjustment is required in patients with hepatic insufficiency , as well in elderly or obese patients .This article will review the pharmacokinetic profile , efficacy data and safety aspects of linagliptin in type 2 diabetes patients .", "label": "", "metadata": {}, "score": "53.45761"}
{"text": "[ Time Frame : Day 29 ] [ Designated as safety issue : No ] .Subjects Who at End of Treatment ( 4 Weeks Post Ramadan ) Achieve ( y / n ) : HbA1c Below 7.0 % ( 53 mmol / Mol ) , and no Confirmed Hypoglycaemic Episodes [ Time Frame : Day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "53.51884"}
{"text": "Three - graded stratification of carbohydrate restriction according to baseline HbA1c levels may provide T2DM patients with optimal objectives for carbohydrate restriction and prevent restriction from being unnecessarily strict .", "label": "", "metadata": {}, "score": "53.61979"}
{"text": "In the United Kingdom Prospective Diabetes Study , one quarter of patients developed microalbuminuria within 10 years of being diagnosed with T2DM [ 16 ] .", "label": "", "metadata": {}, "score": "53.68421"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "53.74438"}
{"text": "Collectively , the results indicate that DPP-4 inhibitors added to metformin may represent a more effective combination in type 2 diabetic patients with unfavorable glucose control in monotherapy .", "label": "", "metadata": {}, "score": "53.95323"}
{"text": "9701 , pp .1606 - 1616 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Aschner , M. S. Kipnes , J. K. Lunceford , M. Sanchez , C. Mickel , and D. E. Williams - Herman , \" Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "54.07175"}
{"text": "Linagliptin shows modest oral bioavailability , but is rapidly absorbed [ 9 , 10 ] .The maximum plasma concentration ( C max ) at steady state is reached on average 1.5 hours after administration of linagliptin 5 mg , once daily [ 11 ] .", "label": "", "metadata": {}, "score": "54.08091"}
{"text": "At baseline , 36 of the 122 patients ( 30 % ) had already been prescribed anti - diabetic drugs by other physicians ( Table 4 ) .", "label": "", "metadata": {}, "score": "54.091988"}
{"text": "Increased GLP-1 can physio- logically inhibit the satiety center in the brain , reduce appetite , and delay stomach emptying [ 18].Although there is no current obvious explanation why only patients in the vildagliptin - metformin treatment group experienced intolerable GI trouble , initiating vildagliptin treatment with a low - dose of metformin in order to ameliorate the GI side effects is advisable .", "label": "", "metadata": {}, "score": "54.146255"}
{"text": "View Article .Deacon CF , Holst JJ : Linagliptin , a xanthine - based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes .", "label": "", "metadata": {}, "score": "54.233887"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "54.28348"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement .", "label": "", "metadata": {}, "score": "54.28348"}
{"text": "Linagliptin administration to patients with liver failure does not require dose adjustment .Although reductions occur in the linagliptin pharmacokinetic parameters as the liver failure degree increases , this has no impact on DPP-4 inhibition [ 6 ] .", "label": "", "metadata": {}, "score": "54.32685"}
{"text": "A recent randomized control trial of sibutramine compared with placebo on cardiovascular effects in obese patients has shown an increase in risk for myocardial infarction , however this increase was n't noted in patients with diabetes [ 64 ] .", "label": "", "metadata": {}, "score": "54.34595"}
{"text": "Table 1 .Baseline patient demographics and clinical characteristics ( treated set ) .eGFR , estimated glomerular filtration rate , according to the Modification of Diet in Renal Disease study equation ; ACE , angiotensin - converting enzyme ; ARB , angiotensin - II receptor blocker .", "label": "", "metadata": {}, "score": "54.35037"}
{"text": "Publications 20 .Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus .John P H Wilding Department of Obesity and Endocrinology , University of Liverpool , Liverpool , United Kingdom Electronic address J Diabetes Complications 29:438 - 44 .", "label": "", "metadata": {}, "score": "54.381073"}
{"text": "Linagliptin had a modest effect on blood pressure , comparable to studies with other DPP-4 inhibitors , which have shown small to neutral effects on blood pressure [ 24 , 26 - 28 ] .", "label": "", "metadata": {}, "score": "54.473255"}
{"text": "The Full Analysis Set ( FAS ) included all treated and randomized patients with a baseline and at least one on - treatment HbA1c measurement available during the first phase of the study .", "label": "", "metadata": {}, "score": "54.578323"}
{"text": "10.1111/j.1742 - 1241.2009.02143.x .PubMed Central View Article PubMed .Hermansen K , Kipnes M , Luo E , Fanurik D , Khatami H , Stein P : Efficacy and safety of the dipeptidyl peptidase-4 inhibitor , sitagliptin , in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin .", "label": "", "metadata": {}, "score": "54.642513"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus . A. Vella , J. S. Lee , M. Camilleri et al . , \" Effects of pramlintide , an amylin analogue , on gastric emptying in type 1 and 2 diabetes mellitus , \" Neurogastroenterology and Motility , vol .", "label": "", "metadata": {}, "score": "54.74537"}
{"text": "J P H Wilding Department of Obesity and Endocrinology , University Hospital Aintree , Liverpool , UK Diabetes Obes Metab 15:750 - 9 .To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin ( HbA1c ) as an add - on to metformin in patients with type 2 diabetes ... .", "label": "", "metadata": {}, "score": "54.78025"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. E. Ratner , D. Maggs , L. L. Nielsen et al . , \" Long - term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over - weight metformin - treated patients with type 2 diabetes mellitus , \" Diabetes , Obesity and Metabolism , vol . 8 , no .", "label": "", "metadata": {}, "score": "54.80124"}
{"text": "Rifampicin , in turn , can reduce the exposure to linagliptin , suggesting that linagliptin efficacy may be reduced by concomitant use of these two drugs [ 12 ] .", "label": "", "metadata": {}, "score": "54.88883"}
{"text": "In this article , aspects of the linagliptin pharmacology will be reviewed , in addition to safety , tolerability and efficacy data on monotherapy or combination therapy .", "label": "", "metadata": {}, "score": "55.031635"}
{"text": "The mean decrease in HbA1c levels was greater in the patients with the highest reductions in carbohydrate intake ( closed circles ) than in those with lower reductions ( open circles ) in each \u0394total energy Group .", "label": "", "metadata": {}, "score": "55.046608"}
{"text": "Garber AJ , Foley JE , Banerji MA , Ebeling P , Gudbjornsdottir S , Camisasca RP , Couturier A , Baron MA .Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequate- ly controlled with a sulphonylurea .", "label": "", "metadata": {}, "score": "55.05186"}
{"text": "Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes .Brief Summary .This trial is conducted in Africa and Asia .", "label": "", "metadata": {}, "score": "55.117783"}
{"text": "No changes were observed in safety and tolerability of linagliptin in patients aged over 65 years [ 6 ] .Cardiovascular safety .The main cause of mortality in T2DM patients is cardiovascular disease ( CVD ) [ 33 ] .", "label": "", "metadata": {}, "score": "55.338917"}
{"text": "A randomized double - blind placebo - controlled study of the long - term efficacy and safety of topiramate in the treatment of obese subjects .", "label": "", "metadata": {}, "score": "55.349743"}
{"text": "A randomized double - blind placebo - controlled study of the long - term efficacy and safety of topiramate in the treatment of obese subjects .", "label": "", "metadata": {}, "score": "55.349743"}
{"text": "When HbA1c results are expressed as % age haemoglobin , the equation describing the relationship is : .In a busy diabetes clinic converting these units can be a challenge .", "label": "", "metadata": {}, "score": "55.366203"}
{"text": "Linagliptin is a highly specific and potent inhibitor of DPP-4 that is currently indicated for the treatment of type 2 diabetes .Clinical studies with linagliptin demonstrated efficacy in reducing glycated hemoglobin ( HbA1c ) levels in type 2 diabetes patients , while maintaining a placebo - like safety and tolerability profile .", "label": "", "metadata": {}, "score": "55.438206"}
{"text": "10.1111/j.1463 - 1326.2010.01326.x .View Article PubMed .Johansen OE , Neubacher D , von Eynatten M , Patel S , Woerle HJ : Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus : a pre - specified , prospective , and adjudicated meta - analysis of a phase 3 programme .", "label": "", "metadata": {}, "score": "55.443604"}
{"text": "10.1016/j.amjmed.2009.12.004 .View Article PubMed .Rizzo M , Rizvi AA , Spinas GA , Rini GB , Berneis K : Glucose lowering and anti - atherogenic effects of incretin - based therapies : GLP-1 analogues and DPP-4 inhibitors .", "label": "", "metadata": {}, "score": "55.446033"}
{"text": "GLP-1 enhances insulin secretion in a glucose - dependent manner , accounting for about 50 - 70 % of the insulin secreted in response to oral glucose [ 34 ] , and suppresses glucagon secretion [ 35 ] .", "label": "", "metadata": {}, "score": "55.571587"}
{"text": "This change from baseline reflects the Week 104 FPG minus the Baseline FPG .Means are treatment adjusted for baseline HbA1c , baseline FPG and number of previous anti - diabetic medications .", "label": "", "metadata": {}, "score": "55.604904"}
{"text": "10.1111/j.1463 - 1326.2008.00914.x .View Article PubMed .Nowicki M , Rychlik I , Haller H , Warren ML , Suchower L , Gause - Nilsson I : Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment .", "label": "", "metadata": {}, "score": "55.83322"}
{"text": "For every 1 % decrease in HbA1c , there was a corresponding weight gain of about 2 kg [ 8 ] .Thus , the effect of antidiabetes agents on weight and obesity status is an important consideration when treating patients with diabetes since obesity , itself , aggravates insulin resistance and cardiovascular risk .", "label": "", "metadata": {}, "score": "56.05181"}
{"text": "Both of these effects depend on plasma glucose concentration , indicating that insu- lin secretion is suppressed and glucagon secretion is stimulat- ed under low - blood glucose conditions .", "label": "", "metadata": {}, "score": "56.095177"}
{"text": "Baseline fasting insulin , C - peptide , HOMA - \u03b2 , and HOMA- IR were similar in the vildagliptin - metformin and glimepiride- metformin groups .", "label": "", "metadata": {}, "score": "56.112545"}
{"text": "419 - 428 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus . D. C. Klonoff , J. B. Buse , L. L. Nielsen et al . , \" Exenatide effects on diabetes , obesity , cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years , \" Current Medical Research and Opinion , vol .", "label": "", "metadata": {}, "score": "56.141403"}
{"text": "11 , pp .1957 - 1960 , 2001 .View at Google Scholar \u00b7 View at Scopus .W. Philip T. James , Ian D. Caterson , Walmir Coutinho et al . , \" Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "56.219147"}
{"text": "There was also a greater reduction in HbA1c in the combination therapy group .Insulin .By way of progressive loss of beta cell function , the majority of patients with diabetes will require insulin therapy to achieve glycemic control .", "label": "", "metadata": {}, "score": "56.288387"}
{"text": "Between April 2010 and December 2011 , we recruited all new outpatients with type 2 diabetes of Haimoto Clinic with HbA1c levels of 6.5 % or above for this study .", "label": "", "metadata": {}, "score": "56.337368"}
{"text": "CONCLUSIONS -These results suggest that in patients with type 2 diabetes , inadequately controlled on sitagliptin with or without metformin , add - on treatment with dapagliflozin provides additional clinical benefit and is well tolerated .", "label": "", "metadata": {}, "score": "56.36874"}
{"text": "Despite weight gain , pioglitazone improved some secondary cardiovascular outcomes with regard to composite of all - cause mortality , nonfatal myocardial infarction , and stroke with multiple effects of lowering cholesterol and blood pressure .", "label": "", "metadata": {}, "score": "56.44724"}
{"text": "We analyzed data to examine whether the effect of \u0394carbohydrate intake on \u0394HbA1c was independent of \u0394total energy intake by comparison of \u0394Hb1c between carbohydrate reduction predominant and less predominant patients stratified by tertile of \u0394total energy intake ( \u0394total energy Groups 1 - 3 ) .", "label": "", "metadata": {}, "score": "56.50308"}
{"text": "This effect was sustained for up to two years after discontinuation of insulin [ 21 ] .Early intensive glucose control had been repeatedly shown to improve microvascular outcomes , however , at the expense of significant weight gain and hypoglycemia [ 6 ] .", "label": "", "metadata": {}, "score": "56.510323"}
{"text": "Of these , 1 patient was not treated .The remaining 8 patients not accounted for in the treated set were removed from all study analyses ( explained in trial report ) due to major good - clinical - practice violations at the site , and the inability to verify the validity of any patient level data .", "label": "", "metadata": {}, "score": "56.52989"}
{"text": "Glimepiride .Patients randomized to receive Glimepiride 1 - 4 mg and metformin .Fasting Plasma Glucose ( FPG )Change From Baseline at Week 104 [ units : mg / dL ] Mean ( Standard Error ) .", "label": "", "metadata": {}, "score": "56.53071"}
{"text": "Changes in body weight Mean body weight at baseline was 66.2\u00b17.8 kg and 69.7\u00b110.2 kg in the glimepiride - metformin and vildagliptin - metformin groups , respectively .", "label": "", "metadata": {}, "score": "56.539307"}
{"text": "View Article .Haimoto H , Sasakabe T , Umegaki H , Wakai K : Reduction in urinary albumin excretion with a moderate low - carbohydrate diet in patients with type 2 diabetes : a 12-month intervention .", "label": "", "metadata": {}, "score": "56.600204"}
{"text": "It is important to consider that patients with T2DM and hypertriglyceridemia exhibit increased risk of pancreatitis [ 7 ] .In clinical studies , 8 pancreatitis cases were reported in 4687 patients on linagliptin and no cases among 1183 patients receiving placebo ; however , no relationship between linagliptin and pancreatitis has been established [ 13 ] .", "label": "", "metadata": {}, "score": "56.654205"}
{"text": "Efficacy of glucose control Mean FPG\u00b1standard deviation was decreased from 8.78\u00b1 2.32 mmol / L at baseline to 7.24\u00b11.64 mmol / L at week 32 in the vildagliptin - metformin group and from 9.34\u00b12.14 mmol/ L to 7.18\u00b11.91 mmol / L in the glimepiride - metformin group .", "label": "", "metadata": {}, "score": "56.735596"}
{"text": "Therefore , the tapering of sulfonylurea doses in patients with lower HbA1c levels is a serious issue even with our moderate LCD .At the start of the moderate - LCD , we tapered the dose of sulfonylureas to about half of baseline to prevent hypoglycemia and monitored blood glucose levels every one or two weeks .", "label": "", "metadata": {}, "score": "56.95489"}
{"text": "Vildagliptin was generally well tolerated in patients with type 2 diabetes , was weight neutral and was associated with a low risk of hypoglycaemia , reflecting its glucose - dependent mechanism of action .", "label": "", "metadata": {}, "score": "57.004326"}
{"text": "Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes .", "label": "", "metadata": {}, "score": "57.05936"}
{"text": "504 - 508 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .P. A. Hollander , P. Levy , M. S. Fineman et al . , \" Pramlintide as an adjunct to insulin therapy improves long - term glycemic and weight control in patients with type 2 diabetes : a 1-year randomized controlled trial , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "57.103333"}
{"text": "275 - 286 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .M. C. Bunck , M. Diamant , A. Corn\u00e9r et al . , \" One - year treatment with exenatide improves \u03b2 -cell function , compared with insulin glargine , in metformin - treated type 2 diabetic patients : a randomized , controlled trial , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "57.107056"}
{"text": "PubMed Central PubMed .Blench S , Ludwig - Schwellinger E , Grafe - Mody U , Withopf B , Wagner K : The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor , linagliptin , in humans .", "label": "", "metadata": {}, "score": "57.251354"}
{"text": "Abstract .OBJECTIVE -To assess the efficacy and safety of dapagliflozin as add - on therapy in patients with type 2 diabetes who were inadequately controlled with a dipeptidyl peptidase-4 inhibitor with or without metformin .", "label": "", "metadata": {}, "score": "57.25974"}
{"text": "10.1124/dmd.109.031476 .View Article .Barnett AH : Linagliptin : a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy .Adv Ther .", "label": "", "metadata": {}, "score": "57.436855"}
{"text": "Treatment of obese subjects with topiramate has recently been associated with significant weight loss in a 6-month dose - ranging study ... .Down - regulation of orexin gene expression by severe obesity in the rats : studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone .", "label": "", "metadata": {}, "score": "57.485207"}
{"text": "10.1136/bmj.321.7258.405 .PubMed Central View Article PubMed .Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HAW : 10-Year follow - up of intensive glucose control in Type 2 Diabetes .", "label": "", "metadata": {}, "score": "57.543274"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .This population includes the FAS further restricted to patients with a baseline FPG and one on - treatment FPG measurement .", "label": "", "metadata": {}, "score": "57.586082"}
{"text": "784 - 790 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Riddle , R. Pencek , S. Charenkavanich , K. Lutz , K. Wilhelm , and L. Porter , \" Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "57.661575"}
{"text": "37 kg / m 2 ) with normal ( 79 % ) or impaired ( 21 % ) glucose tolerance were randomized to lifestyle changes plus either orlistat 120 mg or placebo , three times daily .", "label": "", "metadata": {}, "score": "57.67411"}
{"text": "The efficacy of liraglutide ( 1.2 mg , 1.8 mg , 2.4 mg , or 3.0 mg ) was assessed in obese nondiabetic individuals in a 20-week double - blind , placebo - controlled trial with an open - label orlistat comparator [ 49 ] .", "label": "", "metadata": {}, "score": "57.701515"}
{"text": "CAROLINA : Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes .In different pharmacokinetic drug - drug interaction studies , linagliptin exhibited low potential for drug interaction [ 10 ] .", "label": "", "metadata": {}, "score": "57.789124"}
{"text": "Linagliptin showed no weight increase in monotherapy or in combination with metformin .There was also no change in waist circumference with linagliptin treatment [ 24 ] .", "label": "", "metadata": {}, "score": "57.84056"}
{"text": "We also recorded the doses of lipid - lowering or anti - diabetic drugs ( glibenclamide , gliclazide , glimepiride , nateglinide , metformin , pioglitazone , voglibose , sitagliptin ) taken by the patients .", "label": "", "metadata": {}, "score": "57.876755"}
{"text": "In contrast , patients on metformin had a weight loss of 1.1 kg .Thus , the combination of SU with metformin results in superior glycemic control with less weight gain than SU monotherapy .", "label": "", "metadata": {}, "score": "57.883495"}
{"text": "For these reasons , guidelines for the treatment of T2DM recommend testing for the presence of microalbuminuria - an early indicator of renal dysfunction - at initial diagnosis and in annual follow - up visits [ 5 , 6 ] .", "label": "", "metadata": {}, "score": "57.91267"}
{"text": "Diabet Obes Metab .10.1111/j.1463 - 1326.2009.01046.x .View Article .Forst T , Pfutzner A : Linagliptin , a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile , and efficacy in a broad range of patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "57.94194"}
{"text": "Adverse events were balanced between groups and discontinuation rates were low .At week 48 , signs and symptoms suggestive of genital infection were more frequent with dapagliflozin ( 9.8 % ) than with placebo ( 0.4 % ) .", "label": "", "metadata": {}, "score": "57.97285"}
{"text": "Further , animal studies have shown beneficial effect of GLP-1 hormone on beta cell proliferation and inhibiting apoptosis [ 38 ] .These effects are of particular significance given that beta - cell failure occurs prior to the onset of diabetes .", "label": "", "metadata": {}, "score": "57.994923"}
{"text": "Serum lipid profiles , including serum triglyceride , HDL - cholesterol and LDL - cholesterol , significantly improved in all patients as a result of following our moderate LCD for 6 months ( Table 1 ) .", "label": "", "metadata": {}, "score": "58.135628"}
{"text": "Thus , despite questioning the possibility of an increased risk of adverse events with less selective inhibitors , the clinical relevance and significance of this selectivity are not established [ 6 ] .", "label": "", "metadata": {}, "score": "58.150414"}
{"text": "CV , cardiovascular Adapted from Chade AR , et al .Hypertension 2005;45:1042 - 1049 .Linagliptin is an oral , once - daily dipeptidyl peptidase ( DPP)-4 inhibitor that prevents the inactivation of incretin hormones glucagon - like peptide ( GLP)-1 and glucose - dependent insulinotropic peptide , which stimulate glucose - dependent secretion of insulin .", "label": "", "metadata": {}, "score": "58.17977"}
{"text": "The patients who discontinued medication due to adverse events were not included in the final analysis .The final analyzed patients consisted of 66 males and 36 females , with a mean age of 54 years and an average duration of diabetes of 5.9 years .", "label": "", "metadata": {}, "score": "58.191322"}
{"text": "Indeed , the number of patients on anti - diabetic drugs decreased in the study period , especially in Group 2 .Further studies on patients not taking anti - diabetic drugs will be required to resolve this issue .", "label": "", "metadata": {}, "score": "58.233227"}
{"text": "Considering the potential CV risk associated with severe hypoglycemia , the use of medica- tions associated with a low risk of hypoglycemia for the con- trol and management of blood glucose in patients with type 2 diabetes would be prudent .", "label": "", "metadata": {}, "score": "58.407043"}
{"text": "In 25 patients , medication was eliminated or reduced in the study period while in 12 , it was increased or newly started .Table 4 .", "label": "", "metadata": {}, "score": "58.49164"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .B. Zinman , J. Gerich , J. B. Buse et al . , \" Efficacy and safety of the human glucagon - like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD ) , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "58.558636"}
{"text": "These were also accompanied by greater improvements in beta cell function and insulin resistance .Thus , treatment with orlistat may counteract the weight gain effects associated with SUs and insulin and is currently available over the counter .", "label": "", "metadata": {}, "score": "58.63231"}
{"text": "Long - term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin : a randomized trial .John P H Wilding University Hospital Aintree , Liverpool , United Kingdom Ann Intern Med 156:405 - 15 .", "label": "", "metadata": {}, "score": "58.668716"}
{"text": "In the current study , \u0394HbA1c was not associated with baseline IRI levels , though it was clearly correlated with \u0394carbohydrate .Thus , a higher carbohydrate intake due to poor dietary compliance seems to be a more important as a cause of deterioration of glycemic control than endogeneous insulin secretion .", "label": "", "metadata": {}, "score": "58.88012"}
{"text": "492 - 498 , 1986 .View at Google Scholar \u00b7 View at Scopus .J. J. Meier , B. Gallwitz , S. Salmen et al . , \" Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon - like peptide 1 in patients with type 2 diabetes , \" Journal of Clinical Endocrinology and Metabolism , vol . 88 , no .", "label": "", "metadata": {}, "score": "58.93614"}
{"text": "Vildagliptin improves glycemic control in type 2 diabetic patients either as a monotherapy or adminis- tered in combination with metformin , sulfonylurea , thiazoli- dinedione or insulin [ 11 - 14].", "label": "", "metadata": {}, "score": "58.93809"}
{"text": "View Article .Boden G , Sargrad K , Homko C , Mozzoli M , Stein TP : Effect of a low - carbohydrate diet on appetite , blood glucose levels , and insulin resistance in obese patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "58.967056"}
{"text": "PubMed Central View Article PubMed .Ogawa S , Ishiki M , Nako K , Okamura M , Senda M , Mori T , Ito S : Sitagliptin , a dipeptidyl peptidase-4 inhibitor , decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "59.034393"}
{"text": "Linagliptin administration to patients with renal impairment does not require dosage adjustment [ 6 ] .When administered in a 5 mg dose , less than 1 % of linagliptin is excreted unchanged in the urine .", "label": "", "metadata": {}, "score": "59.03469"}
{"text": "View Article PubMed .Stratton IM , Adler AI , Neil HA , Matthews DR , Manley SE , Cull CA , Hadden D , Turner RC , Holman R : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes ( UKPDS 35 ) : prospective observational study .", "label": "", "metadata": {}, "score": "59.267418"}
{"text": "10.1016/j.plipres.2008.02.003 .View Article .Ann Intern Med .View Article .Haimoto H , Iwata M , Wakai K , Umegaki H : Long - term effects of a diet loosely restricting carbohydrates on HbA1c levels , BMI and tapering of sulfonylureas in type 2 diabetes : a 2-year follow - up study .", "label": "", "metadata": {}, "score": "59.321823"}
{"text": "Alogliptin .EXAMINE : Examination of Cardiovascular Outcomes : Alogliptin vs Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome .", "label": "", "metadata": {}, "score": "59.37468"}
{"text": "We found no correlations for changes in other cardiovascular risk factors , including \u0394body mass index , \u0394IRI , \u0394serum triglyceride and \u0394serum LDL - cholesterol , across the 3 groups , though an increasing trend in \u0394serum HDL - cholesterol was significant ( Table 1 ) .", "label": "", "metadata": {}, "score": "59.44884"}
{"text": "Experimental : Liraglutide+Metformin .Liraglutide 1.8 mg administered once daily subcutaneously , in combination with pre - trial tablet metformin of unchanged dose .Interventions : .", "label": "", "metadata": {}, "score": "59.482716"}
{"text": "Inzucchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , Peters AL , Tsapas A , Wender R , Matthews DR : Management of hyperglycaemia in type 2 diabetes : a patient - centered approach .", "label": "", "metadata": {}, "score": "59.991367"}
{"text": "They were requested to maintain their usual level of physical activity throughout the study .Clinical assessment .We measured the body mass index ( BMI ) , blood pressure ( BP ) and HbA1c level of each patient every month .", "label": "", "metadata": {}, "score": "60.01368"}
{"text": "10.1111/j.1463 - 1326.2010.01350.x .View Article PubMed .Turner RC , Cull CA , Frighi V , Holman RR : Glycemic control with diet , sulfonylurea , metformin , or insulin in patients with type 2 diabetes mellitus : progressive requirement for multiple therapies .", "label": "", "metadata": {}, "score": "60.03472"}
{"text": "The vildagliptin - metformin association seems to have favorable effects on beta - cell function and is characterized by good safety and tolerability profiles when compared with other antidiabetic agents .", "label": "", "metadata": {}, "score": "60.054577"}
{"text": "Ritz E , Schmieder RE , Pollock CA : Renal protection in diabetes : lessons from ONTARGET .Cardiovasc Diabetol .PubMed Central View Article PubMed .", "label": "", "metadata": {}, "score": "60.06063"}
{"text": "Sitagliptin , saxagliptin , and vildagliptin are DPP-4 inhibitors that inhibit the degradation of endogenous GLP-1 .These are available as oral agents .Sitagliptin and saxagliptin are FDA approved for monotherapy and use with metformin for type 2 diabetes .", "label": "", "metadata": {}, "score": "60.06851"}
{"text": "Body weight remained stable up to 24 weeks in the two groups .This combination can be interesting , even for early therapy in patients with an intolerance or contraindication to metformin .", "label": "", "metadata": {}, "score": "60.14637"}
{"text": "In many previous LCDs , absolute goals for carbohydrate intake , such as 150 g / day , were pre - set before starting them [ 3 , 6 , 10 - 17 ] , which ignored patients ' own baseline carbohydrate intakes .", "label": "", "metadata": {}, "score": "60.241493"}
{"text": "The effect of orlistat and sibutramine in type 2 diabetes is also evaluated .The treatment of diabetes should not only focus on glycemic control as its sole intention , but it should factor in the effect of these various agents on weight , as well , since obesity aggravates insulin resistance , beta cell failure , and cardiovascular risk .", "label": "", "metadata": {}, "score": "60.306145"}
{"text": "Multiple regression analyses were performed to examine associations between \u0394cabohydrate ( g / day ) or \u0394%carbohydrate and \u0394HbA1c with adjustment for changes in energy intake ( \u0394total energy intake ) .", "label": "", "metadata": {}, "score": "60.35006"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Patients in the FAS with a valid meal tolerance test ( MTT ) at baseline and at least one valid on - treatment MTT ( MTT104 ) .", "label": "", "metadata": {}, "score": "60.52259"}
{"text": "SUs , when used as monotherapy , are expected to decrease HbA1c by 1 - 2 % [ 10 , 11 ] .In UKPDS , 3,867 newly diagnosed patients with type 2 diabetes were randomized to intensive treatment with sulfonylurea ( chlorpropamide 100 - 500 mg or glibenclamide 2.5 - 20 mg ) , insulin , or conventional dietary management [ 6 ] .", "label": "", "metadata": {}, "score": "60.650517"}
{"text": "The most commonly reported antihypertensive drugs were angiotensin - converting enzyme ( ACE ) inhibitors ( linagliptin , 40.4 % and placebo , 41.1 % ) .", "label": "", "metadata": {}, "score": "60.704174"}
{"text": "These results suggest that the 3-graded moderate LCD was effective for patients with lower HbA1c levels and avoided an unnecessarily strict carbohydrate restriction on them .", "label": "", "metadata": {}, "score": "60.776817"}
{"text": "It controlled fasting plasma glucose levels as well as sulfonylurea treatment in Korean type 2 diabetic subjects .[ Show abstract ] [ Hide abstract ] ABSTRACT : The dipeptidyl peptidase-4 inhibitor vildagliptin ( Galvus \u00ae ) is approved for use as monotherapy and combination therapy in type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "60.784492"}
{"text": "10.1111/j.1463 - 1326.2011.01362.x .View Article PubMed .Matikainen N , Manttari S , Schweizer A , Ulvestad A , Mills D , Dunning BE , Foley JE , Taskinen MR : Vildagliptin therapy reduces postprandial intestinal triglyceride - rich lipoprotein particles in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "60.870506"}
{"text": "10.2337/diabetes.53.9.2375 .View Article .Foster GD , Wyatt HR , Hill JO , McGuckin BG , Brill C , Mohammed BS , Szapary PO , Rader DJ , Edman JS , Klein S : A randomized trial of a low - carbohydrate diet for obesity .", "label": "", "metadata": {}, "score": "60.934326"}
{"text": "6 , pp .2784 - 2791 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. A. DeFronzo , C. Triplitt , Y. Qu , M. S. Lewis , D. Maggs , and L. C. Glass , \" Effects of exenatide plus rosiglitazone on beta - cell function and insulin sensitivity in subjects with type 2 diabetes on metformin , \" Diabetes care , vol .", "label": "", "metadata": {}, "score": "60.939697"}
{"text": "The Wilcoxon test was used to assess the changes in HbA1c levels and other cardiovascular risk factors , total energy and macronutrient intakes due to our moderate LCD , and compare the levels between baseline and after 6 months for all patients .", "label": "", "metadata": {}, "score": "61.12992"}
{"text": "Summary .In recent years , an increasing number of antidiabetes agents , which have varying effects on glycemic control and weight , have become available .", "label": "", "metadata": {}, "score": "61.197197"}
{"text": "There was a weight loss of 3.8 kg in the metformin group compared with a weight gain of 0.4 kg in the metformin - glyburide group .", "label": "", "metadata": {}, "score": "61.340164"}
{"text": "Holman RR , Paul SK , Bethel MA , Matthews DR , Neil HA .10- year follow - up of intensive glucose control in type 2 diabetes .", "label": "", "metadata": {}, "score": "61.39988"}
{"text": "Postgrad Med 2009;121:70 - 100 .Kulasa KM , Henry RR .Pharmacotherapy of hyperglycemia .Expert Opin Pharmacother 2009;10:2415 - 32 .Rosenstock J , Fitchet M. Vildagliptin : clinical trials programme in monotherapy and combination therapy for type 2 diabetes .", "label": "", "metadata": {}, "score": "61.516434"}
{"text": "The implication of this mode of linagliptin excretion is that in patients with kidney disease , no dose adjustment is required [ 8 ] .Clinical studies : efficacy assessment .", "label": "", "metadata": {}, "score": "61.525665"}
{"text": "DPP-4 inhibitor Linagliptin Efficacy Safety Renal impairment Type 2 diabetes .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "61.541634"}
{"text": "10.1016/j.diabres.2007.09.009 .View Article .Nielsen JV , Joensson EA : Low - carbohydrate diet in type 2 diabetes : stable improvement of bodyweight and glycemic control during 44 months follow - up .", "label": "", "metadata": {}, "score": "61.5429"}
{"text": "The long - term efficacy of exenatide was assessed in an open - ended , open - label clinical trial in which patients from three placebo - controlled trials and their open - label extensions were enrolled for 3 years .", "label": "", "metadata": {}, "score": "61.587997"}
{"text": "Glycemic and weight benefits observed at week 24 were maintained through week 48 .Changes from baseline in systolic blood pressure at week 8 were not significantly different between treatment groups .", "label": "", "metadata": {}, "score": "61.605972"}
{"text": "2719 - 2725 , 2003 .View at Google Scholar \u00b7 View at Scopus . A. Flint , A. Raben , A. K. Ersb\u00f8ll , J. J. Holst , and A. Astrup , \" The effect of physiological levels of glucagon - like peptide-1 on appetite , gastric emptying , energy and substrate metabolism in obesity , \" International Journal of Obesity , vol .", "label": "", "metadata": {}, "score": "61.679234"}
{"text": "A review of the response to oral antidiabetes agents in patients with type 2 diabetes .Postgrad Med 2010;122:43 - 51 .Palalau AI , Tahrani AA , Piya MK , Barnett AH .", "label": "", "metadata": {}, "score": "61.683388"}
{"text": "No relevant food effects were observed on the absorption profile of linagliptin [ 10 ] .A strong binding of the inhibitor to the DPP-4 enzyme is important from the pharmacological point of view , to enable a 24-hour inhibition profile and the once - daily dosing .", "label": "", "metadata": {}, "score": "61.711723"}
{"text": "517 - 522 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. A. Dormandy , B. Charbonnel , D. J. Eckland et al . , \" Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study ( PROspective pioglitAzone Clinical Trial in macroVascular Events ) : a randomised controlled trial , \" Lancet , vol .", "label": "", "metadata": {}, "score": "61.718384"}
{"text": "Thus , as opposed to using SUs with metformin that may promote weight gain and run the risk of hypoglycemia , the use of DPP-4 inhibitors with metformin would be expected to result in less weight gain without the risk of hypoglycemia .", "label": "", "metadata": {}, "score": "61.74195"}
{"text": "DPP4-inhibitors are weight neutral whereas GLP-1 analogs are associated with weight loss ( Figure 1 ) .The effect of various antidiabetes medication classes on glycemic control and weight will be reviewed here .", "label": "", "metadata": {}, "score": "61.758358"}
{"text": "Linagliptin has a primarily non - renal route of excretion .It can , therefore , be used without dosage adjustment irrespective of renal function [ 12 ] , suggesting it is worthy of investigation in patients with , or at high risk of developing , renal as well as cardiovascular disease .", "label": "", "metadata": {}, "score": "62.009254"}
{"text": "The DPP-4 inhibitors promote glucose - dependent insulin secretion , i.e. , in the presence of lower blood glucose values , the insulin release is not expected , which contributes to reduce the risk of hypoglycemia [ 16 ] .", "label": "", "metadata": {}, "score": "62.0381"}
{"text": "The aim of this study was to evaluate the effect on body weight and safety of subcutaneously administered recombinant leptin in obese adults and to evaluate whether the timing of recombinant leptin administration influences efficacy ... .", "label": "", "metadata": {}, "score": "62.102776"}
{"text": "Additionally , as linagliptin is just a weak competitive inhibitor of CYP3A4 , there would be a less than 2-fold decrease in the clearance of other drugs metabolized by this pathway , so linagliptin is considered as having low potential for clinically relevant interactions [ 15 ] .", "label": "", "metadata": {}, "score": "62.129936"}
{"text": "GLP-1 analogs ( exenatide and ligraglutide ) are the latest medications used to treat diabetes and have favorable effects on both glycemic and weight control .", "label": "", "metadata": {}, "score": "62.142746"}
{"text": "Selective SGLT2 inhibitors reduce the RTG , thereby increasing glucosuria , and have demonstrated favorable efficacy and safety in patients with T2DM inadequately controlled with diet and exercise and other glucose - lowering treatments .", "label": "", "metadata": {}, "score": "62.216713"}
{"text": "Despite the difficulty , accurate assessment of carbohydrate consumption at baseline and during the course of the dietary treatment would give patients more consistent carbohydrate and energy deficits .", "label": "", "metadata": {}, "score": "62.315716"}
{"text": "Currently , DPP-4 inhibitors represent an important tool in the T2DM therapeutic setting , both for their efficacy in glycemic control , as well as for their safety profile .", "label": "", "metadata": {}, "score": "62.343906"}
{"text": "This paper provides an overview of the clinical results of combination therapy with metformin and the DPP-4 inhibitor vildagliptin in T2DM patients .EXPERT OPINION : Vildagliptin - metformin single - tablet combination is indicated for the treatment of T2DM patients not achieving a sufficient glycemic control at their maximally tolerated dose of metformin .", "label": "", "metadata": {}, "score": "62.353935"}
{"text": "Am J Ther 2010;17:559 - 65 .Zoungas S , Patel A , Chalmers J , de Galan BE , Li Q , Billot L , Woodward M , Ninomiya T , Neal B , MacMahon S , Grobbee DE , Kengne AP , Marre M , Heller S ; ADVANCE Collaborative Group .", "label": "", "metadata": {}, "score": "62.37764"}
{"text": "The study also examined the association between ZAG and adiponectin expression in human adipose tissue , and whether ZAG modulates adiponectin secretion by human adipocytes ... .", "label": "", "metadata": {}, "score": "62.40641"}
{"text": "This suggests that expression of carbohydrate intake in g / day is superior to expressing it as % carbohydrate for the management of patients with type 2 diabetes given moderate LCDs .", "label": "", "metadata": {}, "score": "62.42646"}
{"text": "Secondary efficacy end- points included FPG or 2-h PPG reduction from baseline , as well as HbA1c responder rate and HbA1c reduction according to baseline HbA1c category .", "label": "", "metadata": {}, "score": "62.469555"}
{"text": "Mayo Clin Proc .10.4065/mcp.2010.0713 .PubMed Central View Article PubMed .Chacra AR , Tan GH , Apanovitch A , Ravichandran S , List J , Chen R : Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes : a randomised controlled trial .", "label": "", "metadata": {}, "score": "62.614346"}
{"text": "Pramlintide slows gastric emptying [ 27 ] , attenuates postprandial glucagon secretion [ 28 ] , enhances satiety , and reduces food intake [ 29 ] .", "label": "", "metadata": {}, "score": "62.87156"}
{"text": "View Article .Unger J : Uncovering undetected hypoglycemic events .Diabetes Metab Syndr Obes .View Article .Whitmer RA , Karter AJ , Yaffe K , Quesenberry CP , Selby JV : Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "62.952957"}
{"text": "Abstract .Background .In patients with type 2 diabetes mellitus ( T2DM ) , hypertension and microalbuminuria are predictive markers for increased renal and cardiovascular risk .", "label": "", "metadata": {}, "score": "63.05287"}
{"text": "Homeostasis model assessment of \u03b2 - cell ( HOMA - \u03b2 ) and homeostasis model as- sessment of insulin resistance ( HOMA - IR ) were evaluated to assess pancreatic \u03b2 - cell function and changes in insulin resis- tance , respectively .", "label": "", "metadata": {}, "score": "63.10512"}
{"text": "In this study , therefore , we set a goal in terms of carbohydrate delta - reduction from baseline intake rather than an absolute goal .", "label": "", "metadata": {}, "score": "63.164978"}
{"text": "Diabetologia .10.1007/s00125 - 012 - 2534 - 0 .View Article PubMed .Basi S , Fesler P , Mimran A , Lewis JB : Microalbuminuria in type 2 diabetes and hypertension : a marker , treatment target , or innocent bystander ?", "label": "", "metadata": {}, "score": "63.22808"}
{"text": "The mean reduction in total energy intake was not significantly different between the carbohydrate reduction predominant patients and the carbohydrate reduction less predominant patients in the three \u0394total energy Groups .", "label": "", "metadata": {}, "score": "63.232315"}
{"text": "g. In an uncontrolled open - label extension of the prior 30-week study , 150 patients opted to continue exenatide treatment for another 52 weeks for a total of 82 weeks [ 40 ] .", "label": "", "metadata": {}, "score": "63.261517"}
{"text": "The progressive failure of the pancreatic \u03b2 - cell function contributes to evolutive character of the disease and the need for therapeutic adjustment .After 3 years of diagnosis , about 50 % of diabetic patients will require combination therapy [ 19 ] .", "label": "", "metadata": {}, "score": "63.34186"}
{"text": "In plasma , only the pharmacologically inactive metabolite CD18790 represents over 10 % of the total drug concentration [ 15 ] .Unlike other DPP-4 inhibitors , linagliptin excretion is not performed by the kidneys , but rather through the enterohepatic system , unchanged [ 8 ] .", "label": "", "metadata": {}, "score": "63.422874"}
{"text": "In general , DPP-4 inhibitors have not demonstrated a significant activation or inhibition of CYP system enzymes , suggesting low potential for interaction with drugs metabolized by this pathway ( except saxagliptin ) [ 9 ] .", "label": "", "metadata": {}, "score": "63.43103"}
{"text": "This population includes the treated set ( all patients treated with at least one dose of study drug ) , and non - missing laboratory data .", "label": "", "metadata": {}, "score": "63.498817"}
{"text": "This population includes the treated set ( all patients treated with at least one dose of study drug ) , and non - missing laboratory data .", "label": "", "metadata": {}, "score": "63.498817"}
{"text": "This population includes the treated set ( all patients treated with at least one dose of study drug ) , and non - missing laboratory data .", "label": "", "metadata": {}, "score": "63.498817"}
{"text": "10.1111/j.1463 - 1326.2011.01391.x .View Article PubMed .Adler AI , Stevens RJ , Manley SE , Bilous RW , Cull CA , Holman RR : Development and progression of nephropathy in type 2 diabetes : the United Kingdom Prospective Diabetes Study ( UKPDS 64 ) .", "label": "", "metadata": {}, "score": "63.512222"}
{"text": "This indicates that the 3-graded moderate LCD was sufficiently effective in our patients with a higher HbA1c level .The 3-graded moderate LCD achieved similarly good results in patients in all groups .", "label": "", "metadata": {}, "score": "63.59021"}
{"text": "Dose - ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin .J P H Wilding Department of Obesity and Endocrinology , University Hospital Aintree , Liverpool , UK Diabetes Obes Metab 15:750 - 9 . [ Long - term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin ] .", "label": "", "metadata": {}, "score": "63.590252"}
{"text": "9131 , pp .837 - 853 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. M\u00e4kimattila , K. Nikkil\u00e4 , and H. Yki - J\u00e4rvinen , \" Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus , \" Diabetologia , vol .", "label": "", "metadata": {}, "score": "63.64809"}
{"text": "1577 - 1582 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .T. Vilsb\u00f8ll , T. Krarup , C. F. Deacon , S. Madsbad , and J. J. Holst , \" Reduced postprandial concentrations of intact biologically active glucagon - like peptide 1 in type 2 diabetic patients , \" Diabetes , vol .", "label": "", "metadata": {}, "score": "63.67947"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. E. Kelley , G. A. Bray , F. X. Pi - Sunyer et al . , \" Clinical efficacy of orlistat therapy in overweight and obese patients with insulin - treated type 2 diabetes : a 1-year randomized controlled trial , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "63.687443"}
{"text": "Therefore , in contrast to the conventional glycemic control strategy that results in significant weight gain , we propose that aggressive weight loss with lifestyle modification and metformin remain the foremost strategy followed by the use of incretin analogs .", "label": "", "metadata": {}, "score": "63.802635"}
{"text": "2008 , 31 ( Suppl 2 ) : S194-S201 .View Article PubMed .Chade AR , Lerman A , Lerman LO : Kidney in early atherosclerosis .", "label": "", "metadata": {}, "score": "63.919563"}
{"text": "Diabetes Care . 10.2337/dc12 - 0413 .View Article .Wild S , Roglic G , Green A , Sincree R , King H : Global prevalence of diabetes : estimates for the year 2000 and projections for 2030 .", "label": "", "metadata": {}, "score": "64.02053"}
{"text": "This study was conducted to evaluate metformin in the prevention or delaying of the progression of type 2 diabetes in high - risk patients [ 5 ] .", "label": "", "metadata": {}, "score": "64.03482"}
{"text": "DPP-4 inhibition is an important target for the T2DM treatment , providing increased GLP-1 concentration , with consequent increase of insulin secretion by pancreatic \u03b2cells and reduction of glucagon secretion from pancreatic \u03b1 - cells , which in turn reduces hepatic glucose output [ 6 ] .", "label": "", "metadata": {}, "score": "64.10448"}
{"text": "View Article PubMed .Cox ME , Rowell J , Corsino L , Green JB : Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes : safety , tolerability , and efficacy .", "label": "", "metadata": {}, "score": "64.13212"}
{"text": "10.1007/s00125 - 006 - 0340 - 2 .View Article PubMed .Cobble ME , Frederich R : Saxagliptin for the treatment of type 2 diabetes mellitus : assessing cardiovascular data .", "label": "", "metadata": {}, "score": "64.14748"}
{"text": "Although it is ideal to calculate precise baseline carbohydrate intakes ( g / day ) based on dietary records and give patients individual targets for delta - reductions in carbohydrate intake from baseline , in our experience doing this is too time consuming .", "label": "", "metadata": {}, "score": "64.14756"}
{"text": "We believe that three -graded stratification ( 3-graded moderate LCD ) is more applicable to patients with a wide range of baseline HbA1c levels , especially those with lower HbA1c levels .", "label": "", "metadata": {}, "score": "64.15353"}
{"text": "The chemical structure of linagliptin ( C 25 H 28 N 8 0 2 ) has a xanthine base , differing from other drugs of the same class , and may reflect differences in pharmacokinetic and pharmacodynamic properties ( Figure 1 ) [ 8 , 9 ] .", "label": "", "metadata": {}, "score": "64.29786"}
{"text": "374 , no .9683 , pp .39 - 47 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Astrup , S. R\u00f6ssner , L. Van Gaal et al . , \" Effects of liraglutide in the treatment of obesity : a randomised , double - blind , placebo - controlled study , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "64.41977"}
{"text": "M Brown Department of Medicine , University of Liverpool , PO Box 147 , Liverpool , L69 3GA Br J Pharmacol 132:1898 - 904 .The hypophagic and anti - obesity effects of sibutramine in dietary - obese Wistar rats appear not to be mediated by inhibition of ARC NPY neurones ... .", "label": "", "metadata": {}, "score": "64.46549"}
{"text": "Change From Baseline to End of Ramadan in Glycosylated Haemoglobin ( HbA1c )[ Time Frame : Baseline , day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "64.4788"}
{"text": "For patients with T2DM , however , renal impairment can be a limiting factor in the selection of appropriate antihyperglycemic therapies .Metformin and some sulfonylureas have contraindications or recommended dose adjustments related to renal impairment .", "label": "", "metadata": {}, "score": "64.52333"}
{"text": "Table 3 .Comparison of \u0394HA1c between carbohydrate reduction predominant and less predominant patients : stratified analysis by tertile of \u0394total energy intake .Comparison of \u0394HA1c between carbohydrate reduction predominant and less predominant patients in three Groups stratified by tertile of \u0394total energy intake .", "label": "", "metadata": {}, "score": "64.533066"}
{"text": "Nathan DM .Long - term complications of diabetes mellitus .N Engl J Med 1993;328:1676 - 85 .Nathan DM , Cleary PA , Backlund JY , Genuth SM , Lachin JM , Orchard TJ , Raskin P , Zinman B ; Diabetes Control and Com- plications Trial / Epidemiology of Diabetes Interventions and Complications ( DCCT / EDIC )", "label": "", "metadata": {}, "score": "64.72604"}
{"text": "View Article .Gupta V , Kalra S : Choosing a gliptin .Indian J Endocrinol Metab .Scheen AJ : A review of gliptins in 2011 .", "label": "", "metadata": {}, "score": "64.747444"}
{"text": "Objective .We investigated the effects of three -graded stratification of carbohydrate restriction by patient baseline HbA1c levels on glycemic control and effects of \u0394carbohydrate on decreases in HbA1c levels ( \u0394HbA1c ) in each group .", "label": "", "metadata": {}, "score": "64.75306"}
{"text": "Reducing carbohydrate by 117 g decreased HbA1c by 0.6 % .The effect of \u0394carbohydrate on \u0394HbA1c was smaller than expected .We assume one of the reasons to be that patients received less and less anti - diabetic drugs , especially sulfonylureas , in the course of the study because of concern about hypoglycemia .", "label": "", "metadata": {}, "score": "64.81861"}
{"text": "This was also true for the UACR and blood pressure analyses of change from baseline .Lipid and blood pressure analyses were based on the last value on treatment ( LVOT ) data .", "label": "", "metadata": {}, "score": "64.868004"}
{"text": "10.1111/j.1463 - 1326.2012.01663.x .PubMed Central View Article PubMed .Tremblay AJ , Lamarche B , Deacon CF , Weisnagel SJ , Couture P : Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "64.896515"}
{"text": "9493 , pp .1279 - 1289 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus . Y. Miyazaki , A. Mahankali , M. Matsuda et al . , \" Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "64.901215"}
{"text": "609 - 613 , 2001 .View at Google Scholar \u00b7 View at Scopus .M. A. Nauck , E. Homberger , and E. G. Siegel , \" Incretin effects of increasing glucose loads in man calculated from venous insulin and C - peptide responses , \" Journal of Clinical Endocrinology and Metabolism , vol .", "label": "", "metadata": {}, "score": "64.91535"}
{"text": "Type 2 diabetes mellitus Hypertension Microalbuminuria Linagliptin DPP-4 inhibitor .Electronic supplementary material .The online version of this article ( doi : 10 .1186/\u200b1475 - 2840 - 12 - 60 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "65.01645"}
{"text": "1739 - 1746 , 2010 .View at Google Scholar . A. Gokcel , H. Karakose , E. M. Ertorer , N. Tanaci , N. B. Tutuncu , and N. Guvener , \" Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "65.10166"}
{"text": "11 , pp .1194 - 1199 , 1996 .View at Google Scholar \u00b7 View at Scopus . D. C. Simonson , I. A. Kourides , M. Feinglos , H. Shamoon , and C. T. Fischette , \" Efficacy , safety , and dose - response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM .", "label": "", "metadata": {}, "score": "65.24981"}
{"text": "PPAR agonists for the treatment of cardiovascular disease in patients with diabetes .J P H Wilding Department of Obesity and Endocrinology , University of Liverpool , Liverpool , UK Diabetes Obes Metab 14:973 - 82 .", "label": "", "metadata": {}, "score": "65.349884"}
{"text": "PPAR agonists for the treatment of cardiovascular disease in patients with diabetes .J P H Wilding Department of Obesity and Endocrinology , University of Liverpool , Liverpool , UK Diabetes Obes Metab 14:973 - 82 .", "label": "", "metadata": {}, "score": "65.349884"}
{"text": "Deterioration in the early insulin responses is fre- quently observed in patients with type 2 diabetes , particularly in the Asian population .DPP-4 inhibitors improved pancreat- ic \u00df - cell dysfunction and may be associated with more im- proved responses in Asian than in Caucasian patients [ 24].", "label": "", "metadata": {}, "score": "65.36354"}
{"text": "The adipokine zinc - alpha2-glycoprotein ( ZAG ) is downregulated with fat mass expansion in obesity .T Mracek Obesity Biology Research Unit , School of Clinical Sciences , University of Liverpool , Liverpool , UK Clin Endocrinol ( Oxf )", "label": "", "metadata": {}, "score": "65.56515"}
{"text": "Change in Baseline Lipid Parameter Low Density Lipoprotein ( LDL ) at Week 104 .Measure Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "65.62273"}
{"text": "Dipeptidyl peptidase-4 ( DPP-4 ) inhibitors are among the most recent additions to the therapeutic options for T2DM and are able to increase circulating levels of glucagon - like peptide-1 ( GLP-1 ) and glucose - dependent insulinotropic polypeptide ( GIP ) , thus stimulating glucose - dependent insulin secretion .", "label": "", "metadata": {}, "score": "65.78882"}
{"text": "Hence , medical treatment of diabetes has collectively targeted these various pathophysiological mechanisms .Intensive lifestyle modification with diet and exercise to achieve weight loss of at least 5 - 10 % has been shown to improve glycemic control with improvements in insulin sensitivity and beta cell function [ 5 ] .", "label": "", "metadata": {}, "score": "65.95276"}
{"text": "408 - 416 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .R. A. DeFronzo and A. M. Goodman , \" Efficacy of metformin in patients with non - insulin - dependent diabetes mellitus .", "label": "", "metadata": {}, "score": "65.97044"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .This population includes the treated set ( all patients treated with at least one dose of study drug ) , and non - missing laboratory data .", "label": "", "metadata": {}, "score": "66.18359"}
{"text": "Linagliptin is a potent , long - acting , orally active DPP-4 inhibitor , with demonstrated efficacy as monotherapy and in combination therapy with other oral antidiabetic agents , when administered in a single daily dose .", "label": "", "metadata": {}, "score": "66.26108"}
{"text": "Alternatively , the use of antiobesity agents such as orlistat , phentermine , or sibutramine has been shown to prevent or delay the onset of type 2 diabetes in obese patients and minimize the weight gain associated with SUs and insulin .", "label": "", "metadata": {}, "score": "66.291756"}
{"text": "10.1111/j.1463 - 1326.2012.01565.x .View Article PubMed .Boehringer Ingelheim International GmbH : Tradjenta TM ( linagliptin ) tablets .US prescribing information , 2011 .", "label": "", "metadata": {}, "score": "66.385475"}
{"text": "10 , pp .905 - 917 , 2010 .View at Google Scholar Abstract .Background .A moderate low - carbohydrate diet has been receiving attention in the dietary management of type 2 diabetes ( T2DM ) .", "label": "", "metadata": {}, "score": "66.59505"}
{"text": "J P H Wilding Forschungsgruppe Diabetes und Endokrinologie , Abteilung Adipositas und Endokrinologie , Zentrum f\u00fcr klinische Wissenschaft , Universit\u00e4tsklinik Aintree , Liverpool , UK Dtsch Med Wochenschr 138:S27 - 38 .", "label": "", "metadata": {}, "score": "66.63727"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. H. Xiang , R. K. Peters , S. L. Kjos et al . , \" Effect of pioglitazone on pancreatic \u03b2 -cell function and diabetes risk in Hispanic women with prior gestational diabetes , \" Diabetes , vol .", "label": "", "metadata": {}, "score": "66.813995"}
{"text": "DeFronzo RA .Current issues in the treatment of type 2 diabe- tes .Overview of newer agents : where treatment is going .Am J Med 2010;123(3 Suppl):S38 - 48 .", "label": "", "metadata": {}, "score": "66.964874"}
{"text": "10.1111/j.1464 - 5491.2005.01760.x .View Article .Westman EC , Yancy WS , Mavropoulos JC , Marquart M , McDuffie JR : The effect of a low - carbohydrate , ketogenic diet versus a low - glycemic index diet on glycemic control in type 2 diabetes mellitus .", "label": "", "metadata": {}, "score": "67.04077"}
{"text": "Clearly , the weight gain associated with insulin is a major drawback for treating diabetes .Further studies examining the effects of antiobesity drugs and GLP-1 agonists to combat insulin - induced weight gain are needed .", "label": "", "metadata": {}, "score": "67.09768"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Rosenstock , E. Samols , D. B. Muchmore , and J. Schneider , \" Glimepiride , a new once - daily sulfonylurea : a double - blind placebo - controlled study of NIDDM patients , \" Diabetes Care , vol .", "label": "", "metadata": {}, "score": "67.12354"}
{"text": "Total energy intake was adjusted using the regression model .We indicated changes in clinical ( body mass index ) , biological ( HbA1c , FPG , IRI and serum lipid profiles ) and nutritional [ total energy intake and macronutrient intake ( g / day and % energy ) ] variables separately for each of the 3 groups .", "label": "", "metadata": {}, "score": "67.23101"}
{"text": "No severe hypoglycemia occurred in any of the patients taking vildagliptin - metformin .The frequent adverse events in the vildagliptin - metformin group were GI events such as nausea , vomiting and diarrhea .", "label": "", "metadata": {}, "score": "67.26141"}
{"text": "N Engl J Med 2010;363:1410 - 8 .Wiedeman PE , Trevillyan JM .Dipeptidyl peptidase IV inhibi- tors for the treatment of impaired glucose tolerance and type 2 diabetes .", "label": "", "metadata": {}, "score": "67.288666"}
{"text": "Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients : UK Multimorbidity Study .I Broom Department of Clinical Biochemistry , University of Aberdeen and Grampian University Hospitals Trust , UK Int J Clin Pract 56:494 - 9 .", "label": "", "metadata": {}, "score": "67.31456"}
{"text": "Down - regulation of orexin gene expression by severe obesity in the rats : studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone .", "label": "", "metadata": {}, "score": "67.35801"}
{"text": "We compared our results with two epoch - making studies reported by Westman et al .[14 ] and Gannon et al .[ 23 ] .", "label": "", "metadata": {}, "score": "67.43022"}
{"text": "We also demonstrated that the amount of carbohydrate reduction necessary to achieve a certain HbA1c decrease in each group .Our dietary strategy may provide patients with type 2 diabetes with optimal and practical objectives for carbohydrate restriction and prevent restriction from being unnecessarily strict .", "label": "", "metadata": {}, "score": "67.48729"}
{"text": "5 , pp .951 - 957 , 2010 .View at Google Scholar .J. Weng , Y. Li , W. Xu et al . , \" Effect of intensive insulin therapy on \u03b2 -cell function and glycaemic control in patients with newly diagnosed type 2 diabetes : a multicentre randomised parallel - group trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "67.606346"}
{"text": "View Article PubMed .Deeks ED : Linagliptin : a review of its use in the management of type 2 diabetes mellitus .Drugs .View Article PubMed .", "label": "", "metadata": {}, "score": "67.63404"}
{"text": "Table 2 .DBP , diastolic blood pressure ; HDL , high - density lipoprotein ; LDL , low - density lipoprotein ; LVOT , last value on treatment ; SBP , systolic blood pressure .", "label": "", "metadata": {}, "score": "67.634796"}
{"text": "No meaningful changes were observed in the hematologic , biochemical or urinary analysis of vital signs , nor were any significant increases in liv- er function or muscle enzyme values observed in either group .", "label": "", "metadata": {}, "score": "67.73241"}
{"text": "View Article .Sasakabe T , Haimoto H , Umegaki H , Wakai K : Effects of a moderate low - carbohydrate diet on preferential abdominal fat loss and cardiovascular risk factors in patients with type 2 diabetes .", "label": "", "metadata": {}, "score": "68.26829"}
{"text": "5 , pp .3G-10 G , 2002 .View at Google Scholar \u00b7 View at Scopus .R. Turner , \" Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) , \" Lancet , vol .", "label": "", "metadata": {}, "score": "68.27191"}
{"text": "10.1111/j.1463 - 1326.2012.01565.x .View Article PubMed .Scheen AJ : Linagliptin for the treatment of type 2 diabetes ( pharmacokinetic evaluation ) .", "label": "", "metadata": {}, "score": "68.384605"}
{"text": "Wheeler ML , Dunbar SA , Jaacks LM , Karmally W , Mayer - Davis EJ , Wylie - Rosett J , Yancy WS : Macronutrients , food groups , and eating patterns in the management of diabetes : a systematic review of the literature , 2010 .", "label": "", "metadata": {}, "score": "68.51404"}
{"text": "10.1056/NEJMoa022207 .View Article .Tanaka K , Moriya T , Kanamori A , Yajima Y : Analysis and a long - term follow up of ketosis - onset Japanese NIDDM patients .", "label": "", "metadata": {}, "score": "68.53595"}
{"text": "HbA1c Change at Week 4 [ units : Percent ] Mean ( Standard Deviation ) .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "68.568565"}
{"text": "View Article .Feinman RD : Fad diets in the treatment of diabetes .Curr Diab Rep. 2011 , 11 : 128 - 135 .10.1007/s11892 - 011 - 0178-y .", "label": "", "metadata": {}, "score": "68.60166"}
{"text": "The total energy intake or \u0394total energy intake was adjusted using linear regression .In addition , increasing or decreasing trends in \u0394HbA1c with increasing \u0394total energy intake were tested by linear regression models including a score of 1 , 2 and 3 given to \u0394total energy Group 1 , 2 and 3 stratified by tertile of \u0394total energy intake , respectively .", "label": "", "metadata": {}, "score": "68.83709"}
{"text": "Decreasing trends in \u0394HbA1c , \u0394FPG , \u0394carbohydrate intake and \u0394total energy intake were evident across the 3 groups .Regarding other macronutrients , significant increasing trends in \u0394%fat and \u0394%protein were also evident , but such trends for \u0394fat ( g / day ) and \u0394protein ( g / day ) were not significant across the 3 groups .", "label": "", "metadata": {}, "score": "69.03004"}
{"text": "Glycosylated haemoglobin ( HbA1c ) [ 1 ] [ units : Percent ] Mean ( Standard Deviation ) .Fasting blood plasma glucose ( FPG ) [ 2 ] [ units : mg / dL ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "69.05466"}
{"text": "The mean levels were 6.9 \u00b1 0.4 % for Group 1 , 8.1 \u00b1 0.4 % for Group 2 and 10.6 \u00b1 1.4 % for Group 3 .", "label": "", "metadata": {}, "score": "69.18885"}
{"text": "Barth JH et al .Consensus meeting on reporting glycated haemoglobin and estimated average glucose in the UK : report to the National Director for Diabetes , Department of Health .", "label": "", "metadata": {}, "score": "69.24315"}
{"text": "Combination with metformin .Metformin is considered first - line therapy in most guidelines around the world .Following 3 years of T2DM diagnosis , approximately 50 % of patients will require combination therapy [ 19 ] .", "label": "", "metadata": {}, "score": "69.25538"}
{"text": "2012 , [ Epub ahead of print ] .Stolar M : Glycemic control and complications in type 2 diabetes mellitus .Am J Med .", "label": "", "metadata": {}, "score": "69.36581"}
{"text": "Improved glycaemic control -- an unintended benefit of a nurse - led cardiovascular risk reduction clinic .A Woodward The Walden Diabetes Centre , University Hospital Aintree , Liverpool , UK Diabet Med 22:1272 - 4 .", "label": "", "metadata": {}, "score": "69.558365"}
{"text": "Although better glycemic control was achieved by a greater reduction in carbohydrate intake in this study , the long - term safety of LCDs has not been proved by interventional studies .", "label": "", "metadata": {}, "score": "69.6673"}
{"text": "This suggests that we could adopt the diet for any baseline HbA1c level or amount of carbohydrate intake and achieve equally good results with respect to targets .", "label": "", "metadata": {}, "score": "69.68808"}
{"text": "2009 , 109 : 1173 - 1178 .10.1016/j.jada.2009.04.007 .View Article .Haimoto H , Sasakabe T , Wakai K , Umegaki H : Effects of a low - carbohydrate diet on glycemic control in outpatients with severe type 2 diabetes .", "label": "", "metadata": {}, "score": "69.71246"}
{"text": "Diabetes .Diabetes Mellitus , Type 2 .Intervention ICMJE .Drug : liraglutide .1.8 mg administered subcutaneously ( s.c ., under the skin ) once daily .", "label": "", "metadata": {}, "score": "69.74153"}
{"text": "- Impaired renal function defined as estimated glomerular filtration rate ( eGFR ) below 60 mL / min/1.73 m^2 per Modification of Diet in Renal Disease ( MDRD ) formula ) .", "label": "", "metadata": {}, "score": "70.49378"}
{"text": "Screening calcitonin value equal to or above 50 ng / L .- Personal or family history of medullary thyroid carcinoma ( MTC ) or multiple endocrine neoplasia syndrome type 2 ( MEN 2 ) .", "label": "", "metadata": {}, "score": "71.207344"}
{"text": "For eg .Another useful way to remember these conversions is that 7.0 % is equivalent to 53 mmol / mol .Every % age increase or decrease thereafter is equivalent to 11 mmol / mol .", "label": "", "metadata": {}, "score": "71.25804"}
{"text": "Time Frame .Baseline and week 104 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "71.30518"}
{"text": "Briefly , sulfonylureas , thiazolidinediones , and insulin are associated with weight gain , whereas metformin and amylin analogs are weight neutral or associated with modest weight loss .", "label": "", "metadata": {}, "score": "71.322014"}
{"text": "This article reviews the clinical efficacy and tolerability of vildagliptin in the treatment of type 2 diabetes , as well as summarizing its pharmacological properties .", "label": "", "metadata": {}, "score": "71.501915"}
{"text": "Accordingly , we modified the LCD to suit Japanese patients with type 2 diabetes .The moderate LCD we have used has been shown to be effective in reducing hemoglobin A1c ( HbA1c ) levels in Japanese diabetic patients with lower to higher HbA1c levels without reinforcement with anti - diabetic drugs [ 6 , 10 - 12 ] .", "label": "", "metadata": {}, "score": "71.7681"}
{"text": "Successful cardiovascular risk reduction in Type 2 diabetes by nurse - led care using an open clinical algorithm .A Woodward University Hospital Aintree , Liverpool , UK Diabet Med 23:780 - 7 .", "label": "", "metadata": {}, "score": "71.81036"}
{"text": "View Article PubMed .de Zeeuw D : Albuminuria : a target for treatment of type 2 diabetic nephropathy .Semin Nephrol .10.1016/j.semnephrol.2007.01.002 .", "label": "", "metadata": {}, "score": "71.99488"}
{"text": "This 1-sided p - value should be compared to the 1-sided threshold of 0.0125 for non - inferiority .Due to the pre - specified hierarchial approach , further confirmatory analysis on the Week24 endpoints is only applicable if superiority is already met .", "label": "", "metadata": {}, "score": "72.03429"}
{"text": "View Article .Gannon MC , Nuttall FQ : Effect of a high - protein , low - carbohydrate diet on blood glucose control in people with type 2 diabetes .", "label": "", "metadata": {}, "score": "72.08583"}
{"text": "45 , pp . 1066 - 1068 , 2004 .View at Google Scholar .B. J. Goldstein , \" Insulin resistance as the core defect in type 2 diabetes mellitus , \" American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "72.313614"}
{"text": "Orlistat and sibutramine have been studied in type 2 diabetes populations which will be briefly reviewed here .Orlistat ( Xenical ) .Orlistat is a lipase inhibitor that inhibits the absorption of dietary fat in the gastrointestinal tract by approximately 30 % at dosage of 120 mg three times daily in combination with a mildly hypocaloric diet [ 53 ] .", "label": "", "metadata": {}, "score": "72.34297"}
{"text": "Although long - term safety has not been proved by interventional studies , no serious harm has resulted from following LCDs for several years [ 2 , 5 - 7 ] .", "label": "", "metadata": {}, "score": "72.51109"}
{"text": "10.5551/jat.8193 .View Article .Oza - Frank R , Cheng YJ , Narayan KM , Gregg EW : Trends in nutrient intake among adults with diabetes in the United States : 1988 - 2004 .", "label": "", "metadata": {}, "score": "72.52074"}
{"text": "[ Time Frame : Day -1 , day 29 ] [ Designated as safety issue : No ] .The level of FPG in the blood of fasting patients was addressed to monitor glycaemic control during the period described .", "label": "", "metadata": {}, "score": "72.53718"}
{"text": "Guedes EP has received lecture and/or consultancy fees from companies with interest in type 2 diabetes therapies ( Astra Zeneca , Bristol - Meyers - Squibb , Novo Nordisk , Boehringer - Ingelheim , Torrent and Abbott ) .", "label": "", "metadata": {}, "score": "72.6426"}
{"text": "There was a slight increase in fat intake but it was significant .While there was no change in protein intake over 6 months , % protein significantly increased due to a marked decline in total energy intake .", "label": "", "metadata": {}, "score": "73.00434"}
{"text": "All statistical tests were performed using the SPSS version 12.0 software package ( SPSS Inc. , Chi- cago , IL , USA ) .The means and frequencies of variables were evaluated using Student 's t - test and the \u03c72 test , respectively .", "label": "", "metadata": {}, "score": "73.18413"}
{"text": "SUs , TZDs , and insulin , when used alone or in combination , are usually associated with modest weight gain , whereas metformin and amylin analogues are weight neutral or result in weight loss .", "label": "", "metadata": {}, "score": "73.20593"}
{"text": "Patients who attended the outpatient diabetic clinic of Chungbuk National University Hospital were included , and exclusion criteria were evaluated during screening ( week -2 , visit 1 ) .", "label": "", "metadata": {}, "score": "73.30634"}
{"text": "Drug : metformin .Active Comparator : Sulfonylurea and Metformin .Subjects continued on pre - trial sulfonylurea tablet treatment , in combination with pre - trial tablet metformin of unchanged dose .", "label": "", "metadata": {}, "score": "73.31582"}
{"text": "UK Prospective Diabetes Study ( UKPDS ) Group .Intensive blood - glucose control with sulphonylureas or insulin com- pared with conventional treatment and risk of complications in patients with type 2 diabetes ( UKPDS 33 ) .", "label": "", "metadata": {}, "score": "73.49411"}
{"text": "Thiazolidinediones ( TZDs ) reduce hyperglycemia primarily by improving insulin sensitivity in adipose , skeletal muscle , and liver tissues .These compounds may also have some favorable effects to preserve beta cell function and prevent diabetes development in patients at high risk [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "73.52095"}
{"text": "John P H Wilding University Hospital Aintree , Liverpool , United Kingdom Ann Intern Med 156:405 - 15 .Thiazolidinediones , insulin resistance and obesity : Finding a balance .", "label": "", "metadata": {}, "score": "73.81613"}
{"text": "View Article .Tada N , Maruyama C , Koba S , Tanaka H , Birou S , Teramoto T , Sasaki J : Japanese dietary lifestyle and cardiovascular disease .", "label": "", "metadata": {}, "score": "73.92706"}
{"text": "Awareness of hypoglycemia has recently increased because it is associated with a significant increase in macrovascular events , mortality and dementia [ 21 , 22 ] and hypoglycemia is a major adverse effect of anti - diabetic drugs , chiefly sulfonylureas [ 21 ] .", "label": "", "metadata": {}, "score": "73.95444"}
{"text": "All authors also read and approved the final manuscript .Authors ' Affiliations .Endocrinologist Board of Metabolism Outpatient Clinic from the 481 State Institute for Diabetes and Endocrinology ( IEDE / RJ ) .", "label": "", "metadata": {}, "score": "74.107315"}
{"text": "10.1007/s13340 - 012 - 0069 - 8 .View Article .Gannon MC , Nuttall FQ : Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition .", "label": "", "metadata": {}, "score": "74.259026"}
{"text": "N Engl J Med 2008;358:2560 - 72 .Glucose control and vascular complications in veterans with type 2 diabetes .N Engl J Med 2009;360:129 - 39 .", "label": "", "metadata": {}, "score": "74.27153"}
{"text": "Subjects will continue on their pre - trial metformin tablet treatment , dose unchanged .Drug : sulfonylurea .Subjects will continue on their pre - trial SU tablet treatment , doses unchanged .", "label": "", "metadata": {}, "score": "74.27754"}
{"text": "Eli Lilly .Edif\u00edcio Barra Business , Barra da Tijuca .References .Inzuchi SE , Bergenstal RM , Buse JB , Diamant M , Ferrannini E , Nauck M , Peters AL , Tsapas A , Wender R , Matthews DR : Management of hyperglycemia in type 2 diabetes : a patient - centered approach .", "label": "", "metadata": {}, "score": "74.42575"}
{"text": "Original Primary Outcome Measures ICMJE ( submitted : August 6 , 2013 ) .Change in Fructosamine From Start of Ramadan to End of Ramadan [ Time Frame : Day -1 , day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "74.63951"}
{"text": "This tendency may be attributable to the proposed uncoupling effect that sulfonylureas have on the glucose - dependent effects of incretin therapies [ 23 ] .", "label": "", "metadata": {}, "score": "74.81907"}
{"text": "The T2DM treatment with glitazone , sulfonylurea , or insulin may be associated with weight gain .Most T2DM patients are overweight or obese , so it is not desirable to gain additional weight due to the treatment .", "label": "", "metadata": {}, "score": "75.008575"}
{"text": "Current Primary Outcome Measures ICMJE ( submitted : November 10 , 2015 ) .Change in Fructosamine From Start of Ramadan to End of Ramadan [ Time Frame : Day -1 , day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "75.10409"}
{"text": "Rodriguez A , Cipres L , Tofe S , Polavieja P , Reviriego J. Clinical evaluation of combined therapy for type 2 diabetes .Curr Med Res Opin 2010;26:1171 - 83 .", "label": "", "metadata": {}, "score": "75.19861"}
{"text": "Sulfonylurea is a potent oral hypoglycemic agent and is commonly prescribed as a monotherapy or as a component of combination therapy for the treatment of type 2 diabetic pa- tients over 60 years of age [ 15,16].", "label": "", "metadata": {}, "score": "75.22319"}
{"text": "10.1111/j.1463 - 1326.2007.00744.x .View Article PubMed .Meloni AR , Deyoung MB , Lowe C , Parkes DG : GLP-1 receptor activated insulin secretion from pancreatic beta - cells : mechanism and glucose dependence .", "label": "", "metadata": {}, "score": "75.59339"}
{"text": "P -values less than 0.05 were considered statistically significant .Data are shown as mean \u00b1 SD .All statistical analyses were performed using SPSS ( version 15.0 ; SPSS , Inc. , Chicago , IL , USA ) .", "label": "", "metadata": {}, "score": "75.77537"}
{"text": "Although metformin is the first - line drug in the early pharmacological treatment of T2DM , some patients do not tolerate the drug , or exhibit contraindications [ 16 ] .", "label": "", "metadata": {}, "score": "75.8809"}
{"text": "View Article PubMed .American Diabetes Association : Standards of medical care in diabetes-2012 .Diabetes Care .2012 , 35 ( Suppl 1 ) : 11 - 63 .", "label": "", "metadata": {}, "score": "76.29828"}
{"text": "Any episode of unstable angina , acute coronary event , cerebral stroke / transient ischemic attack ( TIA ) or other significant cardiovascular event as judged by the investigator within 90 days prior to screening . -", "label": "", "metadata": {}, "score": "76.79983"}
{"text": "Recently , several new classes of oral hypoglycemic agents have been introduced [ 8 - 10].Vildagliptin is an oral and highly Original Article .", "label": "", "metadata": {}, "score": "76.98007"}
{"text": "Primary Completion Date .September 2014 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : .Stable is defined as unchanged medication and dose . -", "label": "", "metadata": {}, "score": "76.99353"}
{"text": "Thiazolidinediones , insulin resistance and obesity : Finding a balance .J Wilding Diabetes and Endocrinology Clinical Research Group , Department of Medicine , Clinical Sciences Centre , University Hospital Aintree , Liverpool , UK Int J Clin Pract 60:1272 - 80 .", "label": "", "metadata": {}, "score": "77.05182"}
{"text": "K S Leong Diabetes Centre , Whiston Hospital , Warrington Road , Prescot , Merseyside L35 5DR , UK Clin Endocrinol ( Oxf ) 54:463 - 8 .", "label": "", "metadata": {}, "score": "77.13501"}
{"text": "The role of the kidneys in glucose homeostasis in type 2 diabetes : clinical implications and therapeutic significance through sodium glucose co - transporter 2 inhibitors .", "label": "", "metadata": {}, "score": "77.50174"}
{"text": "The role of the kidneys in glucose homeostasis in type 2 diabetes : clinical implications and therapeutic significance through sodium glucose co - transporter 2 inhibitors .", "label": "", "metadata": {}, "score": "77.50174"}
{"text": "Type 2 diabetes patients have dysfunction in incretin hormones ( as glucagon - like peptide-1 or GLP-1 , and glucose - dependent insulinotropic polypeptide or GIP ) .", "label": "", "metadata": {}, "score": "77.76947"}
{"text": "Obesity - related signals that might mediate this effect have not been identified , but plasma leptin , insulin and glucose are not obviously involved ... .", "label": "", "metadata": {}, "score": "77.925"}
{"text": "Means are treatment adjusted for baseline HbA1c , baseline weight and the number of previous antidiabetic - medications .Time Frame .Baseline and week 104 .", "label": "", "metadata": {}, "score": "78.04794"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 4 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "78.27884"}
{"text": "Low - carbohydrate diet Carbohydrate intake Macronutrient Hemoglobin A1c Stratification Type 2 diabetes .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "78.31769"}
{"text": "values were -0.8 \u00b1 1.3 % for IRI - Group 1 , -1.3 \u00b1 1.5 % for IRI - Group 2 and -0.9 \u00b1 1.4 % for IRI - Group 3 .", "label": "", "metadata": {}, "score": "78.383"}
{"text": "sive diabetes treatment and cardiovascular disease in patients with type 1 diabetes .N Engl J Med 2005;353:2643 - 53 .Page 7 .Effects of intensive glucose lowering in type 2 diabetes .", "label": "", "metadata": {}, "score": "78.456894"}
{"text": "Means are treatment adjusted for baseline HbA1c , baseline 2hr PPG and number of previous anti - diabetic medications .Time Frame .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "78.46163"}
{"text": "Acknowledgment .The authors are grateful to Dr. Charles Faiman for his thoughtful comments and editorial assistance with this paper .Centers for Disease Control and Prevention ( CDC ) , \" Prevalence of overweight and obesity among adults with diagnosed diabetes - United States , 1988 - 1994 and 1999 - 2002 , \" Morbidity and Mortality Weekly Report , vol .", "label": "", "metadata": {}, "score": "78.49858"}
{"text": "The daily carbohydrate intake ranged widely at baseline , from 140 g to 579 g. The average carbohydrate intake ( g / day ) significantly decreased , from 274 \u00b1 78 g ( 54 \u00b1 8 % of total energy ) at baseline to 168 \u00b1 52 g ( 41 \u00b1 11 % ) after 6 months ( Table 2 ) .", "label": "", "metadata": {}, "score": "78.563805"}
{"text": "Means are treatment adjusted for baseline HbA1c , baseline FPG and the number of previous anti - diabetic medications .Time Frame .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "78.58499"}
{"text": "In patients with T2DM and hypertension , urinary albumin is a key prognosticator of both renal and cardiovascular outcomes , with even low levels of albuminuria being associated with progressive renal dysfunction and increased risk of cardiovascular mortality [ 3 ] .", "label": "", "metadata": {}, "score": "78.598755"}
{"text": "Nutr Metab ( Lond ) .View Article .Volek JS , Fernandez ML , Feinman RD , Phinney SD : Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia , fatty acid partitioning , and metabolic syndrome .", "label": "", "metadata": {}, "score": "78.668785"}
{"text": "Mohan V , Yang W , Son HY , Xu L , Noble L , Langdon RB , Ama- truda JM , Stein PP , Kaufman KD .", "label": "", "metadata": {}, "score": "78.76329"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : August 6 , 2013 ) .Fructosamine at End of Ramadan [ Time Frame : Day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "78.89841"}
{"text": "Values in parentheses are the mean daily dose per person for anti - diabetic drugs .Changes in carbohydrate intake ( g / day ) between patients with less medication and those with more medication over 6 months .", "label": "", "metadata": {}, "score": "78.97298"}
{"text": "Time Frame .Week 104 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "78.98439"}
{"text": "Time Frame .Week 104 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "78.98439"}
{"text": "In spite of not having restrictions on total energy intake or fat intake , fat intake did not increase enough to compensate for the remarkable reduction in carbohydrate intake in this study .", "label": "", "metadata": {}, "score": "79.04874"}
{"text": "Diabetes Res Clin Pract 2009;83:106 - 16 .Matsumoto K , Miyake S , Yano M , Ueki Y , Yamaguchi Y , Aka- zawa S , Tominaga Y. Glucose tolerance , insulin secretion , and insulin sensitivity in nonobese and obese Japanese subjects .", "label": "", "metadata": {}, "score": "79.06109"}
{"text": "HH and TS designed the study .HH and TS participated in data collection .HH , TS and KW performed the statistical analysis and all authors interpreted the data .", "label": "", "metadata": {}, "score": "79.14058"}
{"text": "10.1056/NEJMoa0806470 .View Article PubMed .DeFronzo AR : From the triumvirate to the ominous octet : a new paradigm for the treatment of type 2 diabetes melitus .", "label": "", "metadata": {}, "score": "79.179276"}
{"text": "Drug : metformin .Drug : sulfonylurea .Not Provided .Recruitment Information .Recruitment Status ICMJE .Completed .Enrollment ICMJE .Completion Date .", "label": "", "metadata": {}, "score": "79.20029"}
{"text": "Patients being treated with insulin were also excluded because combination therapy consisting of a moderate LCD and insulin has not been investigated .We also excluded patients who were following carbohydrate restriction at baseline based on commercial diet therapies , e.g. Atkins diet .", "label": "", "metadata": {}, "score": "79.23357"}
{"text": "Means are treatment adjusted for baseline HbA1c , baseline weight and the number of previous antidiabetic - medications .Time Frame .Baseline and week 52 .", "label": "", "metadata": {}, "score": "79.475365"}
{"text": "This was first adopted in June 2009 .During the first two years until May 2011 , results were being reported in both units as % age and mmol / mol , so as to enable health professionals and patients to get used to the new units .", "label": "", "metadata": {}, "score": "79.50113"}
{"text": "Metformin .Metformin is an insulin sensitizing agent that serves as the first line agent in treatment of type 2 diabetes and acts by decreasing hepatic glucose production and enhances peripheral tissue sensitivity to insulin .", "label": "", "metadata": {}, "score": "79.52493"}
{"text": "Means are treatment adjusted for baseline HbA1c and the number of previous anti - diabetic medications .Time Frame .Baseline and week 104 .Safety Issue .", "label": "", "metadata": {}, "score": "79.69374"}
{"text": "10.1016/S0168 - 8227(99)00023 - 6 .View Article .Kashiwagi A , Kasuga M , Araki E , Oka Y , Hanafusa T , Ito H , Tominaga M : International clinical harmonization of glycated hemoglobin in Japan : from Japan Diabetes Society to National Glycohemoglobin Program values .", "label": "", "metadata": {}, "score": "79.75296"}
{"text": "Sibutramine is a serotonin - norepinephrine reuptake inhibitor .It acts by decreasing food intake by reducing appetite and increasing satiety [ 59 ] .In a multicenter , double - blind , placebo - controlled study , 348 obese patients ( BMI .", "label": "", "metadata": {}, "score": "79.872955"}
{"text": "Antidiabetes Agents Associated with Weight Gain .Sulfonylureas .The sulfonylureas ( SUs ) have been extensively used in the treatment of type 2 diabetes and are associated with weight gain .", "label": "", "metadata": {}, "score": "79.94092"}
{"text": "Means are treatment adjusted for baseline HbA1c and the number of previous anti - diabetic medications .Time Frame .Baseline and week 52 .Safety Issue .", "label": "", "metadata": {}, "score": "80.36098"}
{"text": "The adverse events most frequently reported with DPP-4 inhibitors are mild infections ( such as nasopharyngitis , urinary tract infection , and upper respiratory tract infections ) and diarrhoea , back pain , headache and hypertension .", "label": "", "metadata": {}, "score": "80.46727"}
{"text": "In 2008 , the FDA ( Food and Drug Administration ) recommended the inclusion of a warning on the package insert of some drugs acting on the incretin system , after case reports of pancreatitis with the use of GLP-1 analogs [ 29 ] .", "label": "", "metadata": {}, "score": "80.653725"}
{"text": "The insulin deficit is the mechanism that promotes the increase of blood glucose levels , and at diagnosis of diabetes , the patient has already lost more than 80 % of beta - cell function [ 5 ] .", "label": "", "metadata": {}, "score": "81.4019"}
{"text": "Use of Antiobesity Agents in Type 2 DM .At present , there are only two antiobesity agents approved for long - term use by the FDA .", "label": "", "metadata": {}, "score": "81.56334"}
{"text": "Patients were not required to calculate daily carbohydrate intakes .While patients were forbidden to consume carbohydrate - containing foods between meals , they were permitted to eat as much protein and fat as they wished , including saturated fats .", "label": "", "metadata": {}, "score": "81.807816"}
{"text": "Plasma glucose concentrations were determined using enzymatic methods ( Shino - Test Co. , Kanagawa , Japan ) .Serum insulin levels were measured using the standard double antibody radioimmunoassay method ( Fujirebio Inc. , Tokyo , Japan ) .", "label": "", "metadata": {}, "score": "82.09747"}
{"text": "Several patients in both treat- ments complained of GI side effects such as metallic taste , re- duced appetite , or dyspepsia .However , the majority of GI symptoms disappeared over time in both treatment groups , and the patients who complained of GI troubles in the initial period of treatment eventually grew tolerant of the medica- tions .", "label": "", "metadata": {}, "score": "82.284744"}
{"text": "Hypothalamic obesity in humans : what do we know and what can be done ?J Pinkney University of Liverpool , Department of Medicine , Diabetes and Endocrinology Research Group , Clinical Sciences Centre , University Hospital Aintree , Longmoor Lane , Liverpool L9 7AL , UK Obes Rev 3:27 - 34 .", "label": "", "metadata": {}, "score": "82.29608"}
{"text": "Details of power calculation , definition of non - inferiority margin , and other key parameters : .The null hypothesis of non - inferiority is rejected if the upper bound of the two - sided 97.5 % confidence interval is less than 0.35 % .", "label": "", "metadata": {}, "score": "82.437614"}
{"text": "Details of power calculation , definition of non - inferiority margin , and other key parameters : .The null hypothesis of non - inferiority is rejected if the upper bound of the two - sided 97.5 % confidence interval is less than 0.35 % .", "label": "", "metadata": {}, "score": "82.437614"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : INTRODUCTION : Type 2 diabetes mellitus ( T2DM ) is pathophysiologically characterized by a combination of insulin resistance and beta - cell dysfunction .", "label": "", "metadata": {}, "score": "82.439865"}
{"text": "Time Frame .Week 52 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "82.85353"}
{"text": "Time Frame .Week 52 .Safety Issue .No .Population Description .Explanation of how the number of participants for analysis was determined .", "label": "", "metadata": {}, "score": "82.85353"}
{"text": "The main protocol for the present study was approved by the Ethical Committee of the Nagoya Tokushukai General Hospital ( approval number : 2010 - 2 - 104 ) and it was also registered in University Hospital Medical Network ( UMIN000003425 ) before its start .", "label": "", "metadata": {}, "score": "82.92708"}
{"text": "No .Population Description .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "83.03244"}
{"text": "No .Population Description .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "83.03244"}
{"text": "Discussion .Vascular complications are the main challenge in the management of T2DM .In patients with T2DM , hypertension and prevalent microalbuminuria are common clinical features that guide treating physicians in assessing risk of cardiovascular and renal outcomes .", "label": "", "metadata": {}, "score": "83.067535"}
{"text": "FDA : . Declarations .Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .", "label": "", "metadata": {}, "score": "83.250046"}
{"text": "Obesity has been increasing in prevalence worldwide and the majority of patients with type 2 diabetes are either overweight or obese .Diabetes management in this population has been difficult since a number of antidiabetes agents are associated with weight gain .", "label": "", "metadata": {}, "score": "83.36934"}
{"text": "Obesity : under - diagnosed and under - treated in hospital outpatient departments .J Cleator Diabetes and Endocrinology Clinical Research Group , Clinical Sciences Centre , University Hospital Aintree , Liverpool , UK Int J Obes Relat Metab Disord 26:581 - 4 .", "label": "", "metadata": {}, "score": "83.8752"}
{"text": "Hypoglycemia was defined as a finger stick glucose concentration of less than 3.9 mmol / L without loss of consciousness .Severe hypoglyce- mia was defined in the patients with transient dysfunction of the central nervous system who were unable to treat them- selves .", "label": "", "metadata": {}, "score": "83.901"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable . \"Overall reductions in FPG levels in all groups were noticeable .", "label": "", "metadata": {}, "score": "84.30429"}
{"text": "Schematic diagram of study designs .Complementary study designs allowed pooling of the data .All protocols were approved by relevant local independent ethical review or institutional review committees .", "label": "", "metadata": {}, "score": "84.748405"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "84.96797"}
{"text": "Direct methods were used to assay serum LDL cholesterol and HDL cholesterol levels ( Daiichi Pure Chemicals Co. , Tokyo , Japan ) .Statistical analysis .", "label": "", "metadata": {}, "score": "85.29556"}
{"text": "A Woodward The Walden Diabetes Centre , University Hospital Aintree , Liverpool , UK Diabet Med 22:1272 - 4 .One hundred and ten patients with Type 2 diabetes were referred into a nurse - led cardiovascular risk reduction clinic .", "label": "", "metadata": {}, "score": "85.309006"}
{"text": "Number of treatment emergent adverse events ( TEAEs )[ Time Frame : Day -1 to day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "85.96013"}
{"text": "Carbohydrate - reduced diet .The main principle of our moderate LCD is to eliminate carbohydrate - rich food once or twice daily , at breakfast and/or dinner [ 6 , 10 - 12 ] .", "label": "", "metadata": {}, "score": "86.00587"}
{"text": "Gender .Both .Ages .18 Years and older .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "86.41751"}
{"text": "An experienced dietician ( Tae Sasakabe ) performed all the dietary assessments and gave instructions to all the participants .The patients had not followed LCDs before the present intervention .", "label": "", "metadata": {}, "score": "86.44033"}
{"text": "J Wilding Thorax 61:928 - 9 .Labome .Org \u00a9 2015 All Rights Researved Princeton , New Jersey 08540 , USA Abstract .Type 2 diabetes mellitus ( T2DM ) has a high prevalence and incidence around the world .", "label": "", "metadata": {}, "score": "86.8037"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Department of Internal Medicine , Haimoto Clinic .Department of Clinical Nutrition , Haimoto Clinic .", "label": "", "metadata": {}, "score": "86.89807"}
{"text": "Introduction .In recent decades , type 2 diabetes mellitus ( T2DM ) has reached epidemic proportions in all regions of the world , with increasing prevalence and incidence rates , in parallel to the obesity epidemic and the dissemination of occidental lifestyle [ 1 ] .", "label": "", "metadata": {}, "score": "86.90685"}
{"text": "Obesity has been increasing in prevalence worldwide and is strongly associated with the development of type 2 diabetes [ 1 ] .Both obesity and diabetes are associated with an increase in morbidity and mortality primarily from cardiovascular disease .", "label": "", "metadata": {}, "score": "87.12163"}
{"text": "-Body Mass Index ( BMI ) equal to or above 20 kg / m^2 . - Subjects who have expressed their intention to fast ( daytime , i.e. between sunrise and sunset ) during Ramadan after receiving medical counselling regarding the risk of fasting .", "label": "", "metadata": {}, "score": "87.18611"}
{"text": "Includes whether analysis was per protocol , intention to treat , or another method .Also provides relevant details such as imputation technique , as appropriate .", "label": "", "metadata": {}, "score": "87.254395"}
{"text": "It is available subcutaneously and due to a short half - life of 2 - 4 hours , it is administered twice daily and at least 60 minutes before meals .", "label": "", "metadata": {}, "score": "87.83804"}
{"text": "[ 3 ] .Other relevant method information , such as adjustments or degrees of freedom : .No text entered .[ 4 ] .", "label": "", "metadata": {}, "score": "88.08922"}
{"text": "[ 3 ] .Other relevant method information , such as adjustments or degrees of freedom : .No text entered .[ 4 ] .", "label": "", "metadata": {}, "score": "88.08922"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "88.19464"}
{"text": "[ Time Frame : Day -1 to day 29 ] [ Designated as safety issue : No ] .Number of Treatment Emergent Adverse Events ( TEAEs )", "label": "", "metadata": {}, "score": "88.54184"}
{"text": "The pathophysiological defects involved in T2DM are numerous and complex .Insulin resistance ( IR ) is an event that precedes and predicts the hyperglycemia characteristic of T2DM , persisting throughout the course of the disease , and is therefore a therapeutic target in the whole evolution process .", "label": "", "metadata": {}, "score": "88.7517"}
{"text": "Significant events and approaches for the overall study following participant enrollment , but prior to group assignment .Lost to Follow - up .Withdrawal by Subject .", "label": "", "metadata": {}, "score": "88.83652"}
{"text": "[ Time Frame : Day -1 , day 29 ] [ Designated as safety issue : No ] .Change from baseline to end of Ramadan in FPG [ Time Frame : Baseline , day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "89.16406"}
{"text": "Change From Baseline to End of Ramadan in Body Weight [ Time Frame : Baseline , day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "89.217186"}
{"text": "Also provides relevant details such as imputation technique , as appropriate .Female .Male .Body mass index ( BMI ) continuous [ units : kg / m^2 ] Mean ( Standard Deviation ) .", "label": "", "metadata": {}, "score": "90.038414"}
{"text": "In another study comparing the efficacies of Table 3 .AE , adverse event ; SAE , serious adverse event , which means to need medical assistance .", "label": "", "metadata": {}, "score": "91.069626"}
{"text": "Fructosamine at End of Ramadan [ Time Frame : Day 29 ] [ Designated as safety issue : No ] .The fructosamine values at the end of Ramadan ( visit 12 ) were presented .", "label": "", "metadata": {}, "score": "91.142426"}
{"text": "[ Time Frame : Baseline , day 29 ] [ Designated as safety issue : No ] .Change From Baseline to End of Ramadan in Body Weight [ Time Frame : Baseline , day 29 ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "91.1625"}
{"text": "Acknowledgments .This study was partly supported by a grant from Chukyo Longevity Medical Research and Promotion Foundation .The authors would like to thank the nurses at Haimoto Clinic for their assistance and excellent patient care .", "label": "", "metadata": {}, "score": "91.35507"}
{"text": "Obesity , particularly intra - abdominal obesity , induces insulin resistance in muscle and liver that leads to glucose intolerance [ 3 ] .Consequently , insulin resistance has long been targeted for diabetes control .", "label": "", "metadata": {}, "score": "91.47057"}
{"text": "The micro- and macrovascular complications , associated with chronic hyperglycemia , represent a major public health problem .Cardiovascular diseases , blindness , renal failure and limb amputations are responsible for frequent hospitalizations and disabilities , resulting in high economic cost for patients and payers [ 1 ] .", "label": "", "metadata": {}, "score": "91.597115"}
{"text": "Type 2 diabetes mellitus ( T2DM ) affects over 300 million people worldwide and is the leading cause of renal and cardiovascular complications [ 1 ] .", "label": "", "metadata": {}, "score": "92.37063"}
{"text": "Department of Endocrinology , Diabetes , and Metabolism , Cleveland Clinic , 9500 Euclid Avenue , Cleveland , OH 44195 , USA .Received 15 June 2010 ; Accepted 26 July 2010 .", "label": "", "metadata": {}, "score": "92.43328"}
{"text": "Population Description .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "93.080574"}
{"text": "Population Description .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "93.080574"}
{"text": "33 , no .6 , pp .1173 - 1175 , 2010 .View at Google Scholar .11 , no .12 , pp .", "label": "", "metadata": {}, "score": "94.2206"}
{"text": "[ Time Frame : Day -1 to day 29 ] [ Designated as safety issue : No ] .A serious AE was an experience that at any dose resulted in any of the following : Death , a life - threatening experience , in - patient hospitalisation or prolongation of existing hospitalisation , a persistent or significant disability or incapacity , congenital anomaly or birth defect , important medical events .", "label": "", "metadata": {}, "score": "94.481766"}
{"text": "Time Frame .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "94.575806"}
{"text": "Time Frame .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "94.575806"}
{"text": "Time Frame .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "94.575806"}
{"text": "10.1111/j.1463 - 1326.2011.01391.x .View Article PubMed .Lancet .10.1016/S0140 - 6736(12)60691 - 6 .View Article PubMed .Int J Clin Pract .", "label": "", "metadata": {}, "score": "94.92152"}
{"text": "CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was re- ported .ACKNOWLEDGMENTS This work was supported by a research grant from Chungbuk National University in 2009 .", "label": "", "metadata": {}, "score": "95.23225"}
{"text": "Any chronic disorder or severe disease which , in the opinion of the investigator might jeopardise subject 's safety or compliance with the protocol . -", "label": "", "metadata": {}, "score": "95.44354"}
{"text": "6 , pp .781 - 792 , 2001 .View at Google Scholar \u00b7 View at Scopus .28 , no .5 , pp .", "label": "", "metadata": {}, "score": "95.545364"}
{"text": "Melo TG is medical manager for Boehringer - Ingelheim do Brasil .Lauand F is medical manager for Eli Lilly do Brasil .Authors ' contributions .", "label": "", "metadata": {}, "score": "96.42296"}
{"text": "122 , no .21 , pp .2554 - 2559 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "96.734085"}
{"text": "Limitations of the study , such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data .", "label": "", "metadata": {}, "score": "97.54878"}
{"text": "12 , pp .2632 - 2637 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "97.80313"}
{"text": "31 , no . 8 , pp .1979 - 1987 , 2008 .View at Google Scholar \u00b7 View at Scopus .27 , no . 1 , pp .", "label": "", "metadata": {}, "score": "99.54811"}
{"text": "4 , pp .406 - 412 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .27 , no . 1 , pp .", "label": "", "metadata": {}, "score": "100.202774"}
{"text": "5 , pp .762 - 768 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "101.63283"}
{"text": "Below are the links to the authors ' original submitted files for images .Competing interests .The authors declare that they have no competing interests .", "label": "", "metadata": {}, "score": "102.333305"}
{"text": "S Coughlin Department of Medicine , Clinical Sciences Centre , University Hospital Aintree , Longmoor Lane , Liverpool L9 7AL , UK Obes Rev 2:267 - 74 .", "label": "", "metadata": {}, "score": "102.70889"}
{"text": "Introduction .A low - carbohydrate diet ( LCD ) is defined as strict carbohydrate restriction to less than 130 g / day or less than 30 % carbohydrate [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "104.03055"}
{"text": "9626 , pp .1753 - 1760 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "104.55269"}
{"text": "10 , pp .2046 - 2055 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at PubMed \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "105.952675"}
{"text": "Declarations .Acknowledgements .The authors were fully responsible for all content and editorial decisions , were involved at all stages of manuscript development , and have approved the final version .", "label": "", "metadata": {}, "score": "107.247284"}
{"text": "Not Provided .Removed Location Countries .Algeria , India , Israel , Lebanon , Malaysia , South Africa , United Arab Emirates Key information relevant to the recruitment process for the overall study , such as dates of the recruitment period and locations .", "label": "", "metadata": {}, "score": "110.7359"}
{"text": "Authors ' original submitted files for images .Below are the links to the authors ' original submitted files for images .Authors ' Affiliations .", "label": "", "metadata": {}, "score": "112.072525"}
{"text": "Department of Geriatrics , Nagoya University Graduate School of Medicine .Department of Cardiac Surgery , Kansai Heart Center .Department of Preventive Medicine , Nagoya University Graduate School of Medicine .", "label": "", "metadata": {}, "score": "112.546875"}
{"text": "PubMed Central View Article PubMed .Lancet .10.1016/S0140 - 6736(12)60691 - 6 .View Article PubMed .Copyright .\u00a9 von Eynatten et al . ; licensee BioMed Central Ltd. 2013 .", "label": "", "metadata": {}, "score": "115.283936"}
{"text": "View Article .Copyright .\u00a9 Haimoto et al . ; licensee BioMed Central Ltd. 2014 .This article is published under license to BioMed Central Ltd.", "label": "", "metadata": {}, "score": "119.84857"}
{"text": "10.1111/j.1365 - 2125.2011.03931.x .PubMed Central View Article PubMed .Copyright .\u00a9 Guedes et al . ; licensee BioMed Central Ltd. 2013 .", "label": "", "metadata": {}, "score": "122.87422"}
{"text": "Federal University of Santa Catarina ( UFSC ) .Brazilian Society of Endocrinology and Metabolism - Santa Catarina state ( SBEM - SC ) - 2011/2012 .", "label": "", "metadata": {}, "score": "124.07322"}
{"text": "This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "136.64389"}
